Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Cardiology/Vascular Diseases | Musculoskeletal

Clinical Trials: Atrial Fibrillation


A listing of clinical trials currently looking for volunteers to enroll in Atrial Fibrillation studies. Click on the closest city to find more detailed information on a research study in your area.

Alabama

Birmingham : 1160.128.1046 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Birmingham : University of Alabama at Birmingham

Clarification of Optimal Anticoagulation Through Genetics

Birmingham : University of Alabama at Birmingham

Does Atorvastatin Prevent Post Operative Atrial Fibrillation After Pulmonary Resection: A Randomized Clinical Study

Birminham : University of Alabama, Birmingham

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Gulf Shores : 1160.129.32023 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

View More »

Huntsville : 1160.128.1045 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Mobile : 1160.128.1003 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Pell City : 1160.129.32172 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Scottsboro : 1160.129.32054 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Tuscaloosa : 1160.129.32174 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Alaska

Jonesboro : 1160.129.32150 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Arizona

Hot Springs : 1160.129.32156 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Lake Havasu City : 1160.129.32151 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Phoenix : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Phoenix : 1160.129.32250 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Phoenix : Heart Rhythm Specialists PC

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

View More »

Phoenixville : 1160.129.32159 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Arkansas

Hot Springs : 1160.128.1067 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Hot Springs : 1160.129.32140 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Little Rock : Arkansas Cardiology, PA

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Little Rock : 1160.129.32014 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Little Rock : 1160.129.32009 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

California

Santa Ana : Coastal Multi-Specialty Research

Cardiovascular outcomes study to evaluate the potential to reduce cardiovascular risk in patients with a recent acute coronary syndrome (ACS) event & type II diabetes mellitus.

Santa Ana : Coastal Multi-Specialty Research

Patients who have Type II diabetes & coronary artery disease, post angiogram or heart attack. This is a phase 3b study. Currently open for enrollment.

Santa Ana : Coastal Multi-Specialty Research

RESCUE cardiovascular clinical trial

View More »

Beverly Hills : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Encinitas : 1160.129.32035 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Fresno : St. Agnes Medical Center

CONcomitant eValuation of Epicor Left atRial Therapy for AF

Fresno : 1160.129.32019 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Hollywood : 1160.129.32230 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

La Jolla : 1160.129.32225 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

La Mesa : 1160.129.32216 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Los Alamitos : 1160.129.32039 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Los Angeles : Ronald Reagan UCLA Medical Center

ABLATE AF Registry Trial

Los Angeles : Good Samaritan Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Los Angeles : Cedars-Sinai Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Los Angeles : Hollywood Heart and Vascular Research Institute

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Los Angeles : Good Samaritan Hospital

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Merced : 1160.129.32043 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Orange : Orange County Heart Institute and Research Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Palo Alto : Stanford Hospital

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Rancho Mirage : 1160.129.32170 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Redwood City : Sequoia Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Sacramento : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Sacramento : University of California Davis Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Sacramento : Regional Cardiology Associates

Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation

Sacramento : Regional Cardiology Associates, Mercy General Hospital

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Sacramento : UC Davis Medical Center

Ventricular Rate Regularization for Improved Quality of Life in Patients With CHF and AF

San Diego : 1160.128.1042 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

San Diego : University of California San Diego Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

San Diego : 1160.129.32017 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

San Francisco : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

San Francisco : University of California at San Francisco Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

San Francisco : University of California San Francisco

Clarification of Optimal Anticoagulation Through Genetics

San Francisco : UCSF

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

San Jose : Good Samaritan Hospital

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Sana Ana : 1160.129.32051 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Santa Monica : Pacific Heart Institute

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Stanford : Stanford University Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Stanford : Stanford University Medical Center

Dual Epicardial Endocardial Persistent Atrial Fibrillation (AF) Study ( Staged DEEP)

Stanford : Stanford University School of Medicine

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Stanford : Stanford Univeristy Medical Center

Use of the Hansen Medical System in Patients With Atrial Fibrillation

Stockton : 1160.129.32102 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Tarzana : Heart Rythm Specialists of Southern California

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Temecula : 1160.129.32167 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Ventura : 1160.129.32205 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Ventura : 1160.129.32196 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Ventura : 1160.129.32249 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Visalia : 1160.129.32104 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Colorado

Aurora : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Aurora : The Medical Center of Aurora

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Aurora : Aurora Denver Cardiology Associates

Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure

Aurora : 1160.129.32031 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Colorado Spring : 1160.128.1005 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

View More »

Colorado Springs : Penrose Saint Francis Health Services

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Colorado Springs : 1160.129.32204 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Colorado Springs : 1160.129.32021 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Denver : 1160.128.1023 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Denver : Colorado Heart and Vascular

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Connecticut

Bridgeport : 1160.128.1016 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Bridgeport : 1160.129.32193 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Bridgeport : 1160.129.32233 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Guilford : 1160.128.1018 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Hartford : Hartford Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

View More »

Milford : 1160.129.32008 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Norwalk : 1160.128.1050 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Norwalk : 1160.129.32074 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Shelton : 1160.129.32152 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Waterbury : 1160.128.1057 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Delaware

Newark : 1160.129.32066 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

District of Columbia

Washington : Otsuka Investigational Site

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

Washington : 1160.129.32202 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Washington DC : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Washington, D.C. : George Washington University Medical Faculty Associates

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Florida

Daytona Beach : Cardiology Research Associates

Atrial Fibrillation

View More »

Atlantis : JFK Medical Center

NAVISTAR® THERMOCOOL® SF Catheter: Observational Study

Bradenton : Blake Medical Center

CONcomitant eValuation of Epicor Left atRial Therapy for AF

Bradenton : Manatee Memorial Hospital

CONcomitant eValuation of Epicor Left atRial Therapy for AF

Bradenton :

REVEAL AF: Incidence of AF in High Risk Patients

Brandon : 1160.128.1032 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Brandon : 1160.129.32144 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Clearwater : 1160.129.32119 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Coral Springs : 1160.128.1021 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Daytona Beach : 1160.128.1027 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Daytona Beach : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Daytona Beach : Daytona Heart Group

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Delray Beach : 1160.129.32048 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Fort Lauderdale : Broward General Medical Center

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Gainesville : University of Florida - Shands Hospital

ABLATE AF Registry Trial

Gainesville : University of Florida

Clarification of Optimal Anticoagulation Through Genetics

Gainesville : 1160.129.32132 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Hollywood : Otsuka Investigational Site

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

Hollywood : 1160.129.32128 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Jacksonvilee : Mayo Clinic Jacksonville

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Jacksonville : 1160.128.1062 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Jacksonville : 1160.128.1019 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Jacksonville : Diagnostic Cardiology Associates PA

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Jupiter : 1160.129.32090 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Lakeland : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Lakeland : 1160.129.32079 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Largo : 1160.128.1054 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Miami : 1160.129.32076 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Miami : 1160.129.32094 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Miami : 1160.129.32222 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Miami : 1160.129.32018 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Miami : 1160.129.32124 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Miami : 1160.129.32212 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Miramar Beach : 1160.129.32125 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

New Smyrna Beach : 1160.129.32005 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Oakland Park : 1160.129.32147 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Orlando : 1160.128.1087 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Orlando : Florida Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Orlando : 1160.129.32182 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Orlando : Florida Hospital

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Pembroke Pines : 1160.129.32026 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Pembroke Pines : 1160.129.32063 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Pensacola : 1160.128.1058 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Pismo Beach : 1160.129.32136 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Port Charlotte : 1160.128.1007 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Port Charlotte : 1160.129.32208 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Rockledge : 1160.128.1060 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Saint Petersburg : 1160.129.32116 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Sarasota : Otsuka Investigational Site

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

Sarasota : 1160.129.32006 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Sarasota : 1160.129.32248 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Seminole : 1160.129.32020 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

St Petersburg : 1160.129.32213 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

St. Petersburg : Northside Hospital and Heart Institute

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

St. Petersburg : 1160.129.32057 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Tallahassee : Tallahassee Memorial Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Tallahassee : 1160.129.32064 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Tampa : Pepin Heart Hospital

ABLATE AF Registry Trial

Tampa : Florida Heart Rhythm-University of South Florida College of Medicine

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Venice : Venice Regional Medical Center

nContactSurgical Numeris-AF Tethered Coagulation System for Treatment of Persistent & LSP AF

Wellington : 1160.129.32037 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Georgia

Atlanta : Saint Joseph's Hospital of Atlanta

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Atlanta : 1160.129.32178 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Atlanta : Emory University Hospital Midtown

Management of New-Onset Postoperative Atrial Fibrillation

Atlanta : Emory University Hospital

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Augusta : Georgia Health Sciences University

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

View More »

Augusta : Georgia Health Sciences University

Clarification of Optimal Anticoagulation Through Genetics

Cumming : 1160.129.32185 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Decatur : 1160.129.32083 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Macon : Georgia Arrhythmia Consultants & Research Institute

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Roswell : 1160.128.1068 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Idaho

Coeurd'Alene : 1160.129.32096 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Illinois

Barrington : Alexian Brothers Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Belleville : 1160.129.32071 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Chicago : Otsuka Investigational Site

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

Chicago : Rush University Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Chicago : Northwestern Memorial Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

View More »

Chicago : 1160.129.32065 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Chicago : 1160.129.32044 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Chicago : Northwestern University

Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring

Evanston : NorthShore University Health System

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Evanston : NorthShore University Health System

CONcomitant eValuation of Epicor Left atRial Therapy for AF

Hinsdale : 1160.129.32117 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Maywood : Loyola University Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Maywood : Loyola University Medical Center

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Maywood : Loyola University Chicago

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Melrose Park : 1160.128.1073 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Melrose Park : 1160.129.32003 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Morton : 1160.129.32133 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Springfield : Prairie Heart Institute

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Winfield : 1160.128.1048 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Indiana

Bloomington : 1160.129.32106 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Brownsburg : 1160.129.32001 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Hammond : 1160.129.32046 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Indianapolis : 1160.128.1029 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Indianapolis : Heart Center of Indiana

ABLATE AF Registry Trial

View More »

Indianapolis : St. Francis Heart Center

ABLATE AF Registry Trial

Indianapolis : Indiana University Medical Center, School of Medicine

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Indianapolis : Saint Vincent Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Muncie : Medical Consultants, P.C.

Ibutilide Administration During Pulmonary Vein Ablation

Munster : Community Hospital

CONcomitant eValuation of Epicor Left atRial Therapy for AF

Iowa

Ames : 1160.129.32042 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Waterloo : 1160.129.32055 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

West Des Moines : Mercy Medical Center-Iowa Heart Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

West Des Moines : 1160.129.32089 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Kansas

Kansas City : The University of Kansas Medical Center

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Kansas City : University of Kansas Hospitals

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Overland Park : 1160.128.1079 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Overland Park : 1160.129.32029 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Kentucky

Bowling Green : 1160.129.32010 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Elizabeth : 1160.129.32025 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Lexington : Central Baptist Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Lexington : Central Baptist Hospital

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Lexington : Central Baptist Hospital

Vdrive Evaluation of Remote Steering and Testing in Lasso Electrophysiology Procedures Study

View More »

Owensboro : 1160.129.32059 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Louisiana

Alexandria : 1160.129.32176 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Baton Rouge : 1160.128.1008 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Bossier City : 1160.129.32201 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Hammond : 1160.129.32045 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Lafayette : 1160.129.32056 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

View More »

Lake Charles : 1160.129.32169 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Lake Charles : 1160.129.32235 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

New Orleans : Otsuka Investigational Site

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

New Orleans : Tulane University Health Science Center

Clarification of Optimal Anticoagulation Through Genetics

Slidell : 1160.129.32164 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Maine

Auburn : 1160.128.1025 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Biddeford : 1160.129.32122 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Maryland

Annapolis : 1160.129.32226 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Baltimore : Johns Hopkins Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Baltimore : University of Maryland School of Medicine

Clarification of Optimal Anticoagulation Through Genetics

Baltimore : Midatlanatic Cardiovascular Associates, PA; Union Memorial Hospital

CONcomitant eValuation of Epicor Left atRial Therapy for AF

Baltimore : 1160.129.32228 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

View More »

Baltimore : Johns Hopkins Hospital

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Baltimore : University of Maryland

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Baltimore : Johns Hopkins

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Glen Burnie : 1160.129.32247 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Salisbury : 1160.128.1012 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Salisbury : 1160.129.32148 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Salisbury : 1160.129.32155 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Silver Spring : Washington Adventist Hospital

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Takoma Park : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Takoma Park : Washington Adventist Hospital

NAVISTAR® THERMOCOOL® SF Catheter: Observational Study

Towson : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Towson : 1160.129.32229 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Massachusetts

Ayer : 1160.129.32203 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Boston : Massachusetts General Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Boston : Brigham and Womens Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Boston : Brigham and Women's Hospital

Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation

Boston : Beth Israel Deaconess Medical Center

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

View More »

Boston : Brigham and Women's Hospital

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Boston : Massachusetts General Hospital

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Boston : Brigham and Women's Hospital

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Boston : Massachusetts General Hospital

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Fall River : 1160.129.32013 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Worcester : Otsuka Investigational Site

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

Michigan

Alpena : 1160.129.32036 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Ann Arbor : University of Michigan Cardiovascular Center

Effects of Fish Oil on Post Ablation Arrhythmias

Bay City : 1160.129.32234 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Detroit : Henry Ford Hospital

Clarification of Optimal Anticoagulation Through Genetics

Flint : 1160.129.32047 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

View More »

Grand Blanc : 1160.129.32168 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Grand Rapids : Spectrum Health

ABLATE AF Registry Trial

Grand Rapids : Spectrum Health

Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure

Lansing : Thoracic & Cardiovascular Healthcare Foundation

ABLATE AF Registry Trial

Lansing : 1160.129.32052 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Marquette : 1160.129.32142 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Mount Clemens : 1160.129.32232 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Muskegon : 1160.128.1017 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Niles : 1160.129.32053 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Rochester : 1160.129.32134 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Rochester Hills : 1160.128.1015 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Royal Oak : William Beaumont Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Royal Oak : William Beaumont Hospital

CONcomitant eValuation of Epicor Left atRial Therapy for AF

Royal Oak : Beaumont Hospital

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Royal Oak : William Beaumont Hospital

Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery

Saginaw : 1160.129.32075 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Saginaw : 1160.129.32231 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Traverse City : Munson Medical Center

ABLATE AF Registry Trial

Troy : William Beaumont Hospital

Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery

Ypsilanti : Saint Joseph Mercy Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Minnesota

Chaska : 1160.129.32024 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Minneapolis : Minneapolis V.A. Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Minneapolis : University of Minnesota

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Minneapolis : Minneapolis Heart Institute Foundation/Abbott NW Hospital

CONcomitant eValuation of Epicor Left atRial Therapy for AF

Minneapolis : Park Nicollet Institute

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

View More »

Minneapolis : Abbott Northwestern Hospital

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Rochester : Mayo Clinic Rochester

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Rochester : Mayo Clinic College of Medicine

Clarification of Optimal Anticoagulation Through Genetics

Rochester : Mayo Clinic Rochester/St. Mary's Hospital

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Rochester : Mayo Clinic

Use of the Hansen Medical System in Patients With Atrial Fibrillation

Saint Paul : HealthEast St. Joseph's Hospital

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

St Cloud : 1160.129.32190 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

St. Louis Park : Park Nicollet Methodist Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

St. Paul : United Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

St. Paul : Saint Joseph's Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

St. Paul : HealthEast St. Joseph's Hospital

CONcomitant eValuation of Epicor Left atRial Therapy for AF

Mississippi

Tupelo : 1160.128.1004 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Missouri

Columbia : 1160.128.1014 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Kansas City : 1160.128.1047 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Kansas City : Mid-America Heart Institute

Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure

St Louis : 1160.129.32184 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

St. Louis : Washington University/Barnes Jewish Hospital

ABLATE AF Registry Trial

View More »

St. Louis : Saint John's Mercy Heart Health Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

St. Louis : Washington University School of Medicine

Clarification of Optimal Anticoagulation Through Genetics

St. Louis : 1160.129.32143 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

St. Louis : 1160.129.32101 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Montana

Great Falls : 1160.128.1069 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Kalispell : 1160.128.1011 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Kalispell : 1160.129.32165 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Missoula : The International Heart Institute of Montana

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Nebraska

Lincoln : Nebraska Heart Hospital

ABLATE AF Registry Trial

Papillion : 1160.129.32199 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Nevada

Henderson : Cardiovascular Consultants of Nevada

Safety of Amiodarone and Ranolazine Together in Patients With Angina

Las Vegas : Cardiovascular Consultants of Nevada

Safety of Amiodarone and Ranolazine Together in Patients With Angina

Reno : 1160.129.32180 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

New Jersey

Bridgewater : 1160.129.32154 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Camden : Cooper University Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Camden : Cooper University Hospital

CONcomitant eValuation of Epicor Left atRial Therapy for AF

Elmer : 1160.128.1039 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Englewood : 1160.129.32181 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

View More »

Flemington : 1160.128.1035 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Hackensack : Hackensack University Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Hackensack : Hackensack University Medical Center

CONcomitant eValuation of Epicor Left atRial Therapy for AF

Haddon Heights : 1160.129.32179 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Hammonton : 1160.129.32198 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Linden : 1160.129.32030 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Neptune : 1160.129.32049 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

News Brunswick : Robert Wood Johnson University Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Ocean : 1160.129.32242 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Ridgewood : Valley Health System

Catheter Ablation for Recently Diagnosed Paroxysmal Atrial Fibrillation

Ridgewood : The Valley Hospital

Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure

Ridgewood : 1160.129.32221 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Ridgewood : The Valley Hospital

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Somerset : 1160.129.32099 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

South Plainfield : 1160.129.32007 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Voorhees : 1160.129.32069 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

New Mexico

Albuquerque : 1160.128.1036 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

New York

New York : Biomedical Research Alliance of New York

Paroxysmal Atrial Fibrillation (PAF)

View More »

Albany : Albany Associates in Cardiology

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Bronx : Montefiore Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Bronx : Montefiore Medical Center

Clarification of Optimal Anticoagulation Through Genetics

Bronxville : 1160.129.32084 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Brooklyn : 1160.129.32246 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Huntington : 1160.129.32195 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Mineola : 1160.128.1078 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Mineola : 1160.129.32038 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

New York : 1160.128.1083 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

New York : Columbia University Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

New York : Saint Lukes-Roosevelt Hospital Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

New York : Mount Sinai School of Medicine

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

New York : New York University Langone Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

New York : Mount Sinai School of Medicine

Clarification of Optimal Anticoagulation Through Genetics

New York : Mount Sinai School of Medicine

Deviating the Esophagus in Atrial Fibrillation Ablation

New York : 1160.129.32110 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

New York : Mount Sinai School of Medicine

Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation

New York : St. Luke's Roosevelt Hospital

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

New York : Mount Sinai Medical Center

TOCCASTAR - TactiCath Contact Force Ablation Catheter Study for Atrial Fibrillation

NY : Mt. Sinai Hospital

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Poughkeepsie : 1160.128.1001 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Rochester : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Rochester : University of Rochester Medical Center

CONcomitant eValuation of Epicor Left atRial Therapy for AF

Rochester : University of Rochester Medical Center

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Roslyn : St. Francis Hospital

CONcomitant eValuation of Epicor Left atRial Therapy for AF

Staten Island : Staten Island University Hosptial

Randomized Double Blind Control Trial on Effects of Ranolazine on New Onset Atrial Fibrillation

Stony Brook : Stony Brook University Hospital and Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Stony Brook : Stony Brook Univeristy Medical Center

Use of the Hansen Medical System in Patients With Atrial Fibrillation

Syracuse : 1160.129.32015 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Syracuse : 1160.129.32139 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Utica : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Williamsville : 1160.129.32016 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Williamsville : 1160.129.32209 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

North Carolina

Asheboro : 1160.129.32194 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Asheville : 1160.128.1022 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Asheville : Mission Hospital, Inc

CONcomitant eValuation of Epicor Left atRial Therapy for AF

Chapel Hill : University of North Carolina at Chapel Hill

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Charlotte : The Sanger Clinic, PA

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

View More »

Charlotte : Carolinas Medical Center/Sanger Heart & Vascular

Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure

Durham : Duke University Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Durham : Duke University

Clarification of Optimal Anticoagulation Through Genetics

Durham : Duke University Medical Center

CONcomitant eValuation of Epicor Left atRial Therapy for AF

Durham : Duke University Medical Center

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Durham : Duke University

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Durham : Duke University Medical Center

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Durham : Duke University Health System

Use of the Hansen Medical System in Patients With Atrial Fibrillation

Gastonia : 1160.128.1052 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Greensboro : 1160.129.32022 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Hickory : 1160.129.32070 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

High Point : 1160.129.32033 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Jacksonville : 1160.129.32114 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Lenoir : 1160.129.32072 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Pinehurst : 1160.129.32073 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Raleigh : 1160.129.32162 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Statesville : 1160.128.1071 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Wilson : 1160.129.32215 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Winston-Salem : Wake Forest University Health Sciences

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

North Dakota

Fargo : 1160.129.32118 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Minot : 1160.129.32220 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Ohio

Cincinnati : Good Samaritan Hospital

ABLATE AF Registry Trial

Cincinnati : Cardiology Center of Cincinnati

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Cincinnati : Medisync

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Cincinnati : University of Cincinnati Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Cincinnati : Bethesda North Hospital

NAVISTAR® THERMOCOOL® SF Catheter: Observational Study

View More »

Cincinnati : Bethesda North Hospital l TriHealth Hatton Institute

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Cleveland : Otsuka Investigational Site

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

Cleveland : Cleveland Clinic

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Cleveland : University Hospital of Cleveland

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Cleveland : Cleveland Clinic Foundation

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Cleveland : Cleveland Clinic

Siemens 3-D C-Arm CT of the Heart Chambers

Cleveland : Cleveland Clinic Foundation

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Columbus : Ohio State University Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Columbus : The Ohio State University

Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure

Columbus : Ohio State University

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Columbus : Ohio State University

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Fairview Park : 1160.129.32061 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Gallipolis : 1160.129.32011 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Hudson : 1160.129.32060 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Kettering : 1160.129.32183 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Marion : 1160.129.32158 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Miamisburg : 1160.129.32012 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Springfield : 1160.129.32244 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Toledo : Otsuka Investigational Site

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

Toledo : University of Toledo

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Youngstown : 1160.129.32032 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Oklahoma

Oklahoma City : Oklahoma Heart Hospital

ABLATE AF Registry Trial

Oklahoma City : University of Oklahoma

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Oklahoma City : OU Medical Center

Ranolazine for the Prevention of Atrial Fibrillation After Electrical Cardioversion

Tulsa : Oklahoma Heart Institute

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Tulsa : Oklahoma Heart Institute

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Oregon

Bend : 1160.128.1053 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Hillsboro : 1160.128.1033 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Portland : Oregon Health and Science University

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Portland : Providence Saint Vincent Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Portland : 1160.129.32163 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

View More »

Portland : Providence Heart and Vascular Institute

nContactSurgical Numeris-AF Tethered Coagulation System for Treatment of Persistent & LSP AF

Pennsylvania

Altoona : 1160.128.1037 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Camp Hill : 1160.128.1034 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Camp Hill : 1160.129.32236 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Camp Hill : Capital Cardiovascular Associates

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Carnegie : 1160.129.32086 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

View More »

Chambersburg : 1160.129.32206 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Danville : Geisinger Wyoming Valley Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Doylestown : Central Bucks Specialists-Doylestown Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Doylestown : Doylestown Cardiology Associates/Central Bucks

Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure

Doylestown : 1160.129.32157 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Doylestown : Doylestown Hospital

NAVISTAR® THERMOCOOL® SF Catheter: Observational Study

Doylestown : Doylestown Cardiology Associates

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Harleysville : 1160.129.32113 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Harrisburg : Pinnacle Health

ABLATE AF Registry Trial

Harrisburg : Pinnacle Health

ABLATE Post Approval Study - Synergy Ablation Lesions for Non-Paroxysmal AF

Hershey : Penn State University Cardiovascular Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Jersey Shore : 1160.129.32127 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Lancaster : Lancaster Heart & Stroke Foundation

Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure

Lancaster : Lancaster Heart & Stroke

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Langhorne : 1160.128.1010 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Lansdale : 1160.129.32153 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

North Wales : Call for Information

Study of Normal Conditions of Use, Dosing, and Safety of Intravenous (IV) Administration of Vernakalant (MK-6621-049)

Penndel : 1160.129.32115 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Philadelphia : Drexel University College of Medicine

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Philadelphia : University of Pennsylvania Health System

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Philadelphia : Hospital of the University of Pennsylvania

Clarification of Optimal Anticoagulation Through Genetics

Philadelphia : Hospital of the University of Pennsylvania

Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation

Philadelphia : Hospital of the University of Pennsylvania

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Philadelphia : Hospital of the University of Pennsylvania

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Philadelphia : University of Pennslyvania

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Pittsburgh : 1160.128.1056 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Pittsburgh : University of Pittsburgh Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Pittsburgh : V.A. Pittsburgh Healthcare System

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Pittsburgh : University of Pittsburgh Medical Center

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Sayre : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Uniontown : 1160.128.1065 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Warminster : 1160.129.32109 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Wynnewood : Otsuka Investigational Site

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

Wynnewood : Lankenau Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Yardley : 1160.129.32137 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

South Carolina

Anderson : 1160.129.32160 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Anderson : 1160.129.32243 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Beaufort : 1160.129.32002 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Charleston : 1160.128.1043 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Charleston : Medical University of South Carolina

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

View More »

Charleston : Medical University of South Carolina

Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure

Charleston : Medical University South Carolina

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Columbia : 1160.129.32050 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Greenville : Greenville Memorial Hospital

Use of the Hansen Medical System in Patients With Atrial Fibrillation

Myrtle Beach : 1160.129.32108 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

South Dakota

Rapid City : 1160.128.1040 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Tennessee

Chatanooga : 1160.129.32217 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Knoxville : 1160.129.32080 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Knoxville : 1160.129.32082 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Memphis : Baptist Memorial Hospital

nContactSurgical Numeris-AF Tethered Coagulation System for Treatment of Persistent & LSP AF

Nashville : Vanderbilt University Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

View More »

Nashville : Vanderbilt University

Clarification of Optimal Anticoagulation Through Genetics

Nashville : St. Thomas Research Institute

Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure

Nashville : Vanderbilt Medical School

Evaluating the Effectiveness of Fish Oil Supplements at Reducing the Recurrence of Atrial Fibrillation

Nashville : 1160.129.32186 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Nashville : Saint Thomas Research Institute

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

New Tazewell : 1160.129.32223 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Texas

Houston : DM Clinical Research

Atrial Fibrillation - Houston, TX

View More »

Austin : Texas Cardiac Arrhythmia

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Austin : Texas Cardiac Arrhythmia Research Foundation

Clinical Evaluation of the Blazer Open-Irrigated Ablation Catheter for the Treatment of Paroxysmal Atrial Fibrillation

Austin : 1160.129.32145 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Austin : Austin Heart PA

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Austin : Texas Cardiac Arrhythmia Research Foundation

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Austin : Texas Cardiac Arrhythmia Research Foundation (TCARF)

Use of the Hansen Medical System in Patients With Atrial Fibrillation

Austin : Texas Cardiac Arrhythmia Institute

Vdrive Evaluation of Remote Steering and Testing in Lasso Electrophysiology Procedures Study

Beaumont : 1160.129.32095 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Dallas : Baylor Heart and Vascular Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Dallas : University of Texas Southwestern Medical Center

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Dallas : Baylor Heart and Vascular

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Dallas : Baylor Research Institute

Vdrive Evaluation of Remote Steering and Testing in Lasso Electrophysiology Procedures Study

Fort Worth : Baylor All Saints Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Fort Worth : 1160.129.32097 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Fort Worth : Plaza Medical Center

NAVISTAR® THERMOCOOL® SF Catheter: Observational Study

Galveston : University of Texas Medical Branch

Clarification of Optimal Anticoagulation Through Genetics

Grapevine : 1160.129.32105 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Houston : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Houston : Otsuka Investigational Site

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

Houston : University of Texas Health Science Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Houston : Texas Heart Institute at St. Luke's Episcopal Hospital

CONcomitant eValuation of Epicor Left atRial Therapy for AF

Houston : 1160.129.32092 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Houston : 1160.129.32027 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Houston : 1160.129.32100 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Houston : 1160.129.32111 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Houston : 1160.129.32123 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Houston : Methodist Hospital

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Houston : Houston Methodist

Use of the Hansen Medical System in Patients With Atrial Fibrillation

Humble : 1160.129.32219 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Katy : 1160.129.32171 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Killeen : 1160.128.1006 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Kingwood : 1160.129.32211 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

McKinney : 1160.128.1061 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

New Braunfels : 1160.129.32189 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

North Richland Hills : 1160.129.32177 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Odessa : 1160.129.32197 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Plano : The Heart Hospital Baylor Plano

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Plano : Baylor Research Institute

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

San Antonio : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

San Antonio : South Texas Cardiovascular Consultants

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

San Antonio : 1160.129.32187 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Seguin : 1160.129.32191 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Sugar Land : 1160.129.32040 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Sugar Land : 1160.129.32068 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Temple : Scott and White Memorial Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Tomball : 1160.129.32091 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Waco : 1160.129.32093 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Whitney : 1160.129.32175 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Utah

Bountiful : Otsuka Investigational Site

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

Murray : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Murray : Intermountain Medical Center

Clarification of Optimal Anticoagulation Through Genetics

Murray : Intermountain Medical Center

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Ogden : McKay-Dee Hospital Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

View More »

Provo : Utah Valley Regional Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Salt Lake City : St. Mark's

ABLATE AF Registry Trial

Salt Lake City : Otsuka Investigational Site

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

Salt Lake City : Intermountain Medical Center-LDS Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Salt Lake City : University of Utah Health Care

Clarification of Optimal Anticoagulation Through Genetics

Salt Lake City : 1160.129.32034 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Virginia

Burke : 1160.129.32166 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Charlottesville : University of Virginia Health System

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Charlottesville : University Of Virginia Health System

Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation

Charlottesville : University of Virginia Health System

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Charlottesville : Univeristy of Virginia

Use of the Hansen Medical System in Patients With Atrial Fibrillation

View More »

Chesapeake : 1160.129.32004 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Danville : 1160.128.1077 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Danville : 1160.129.32067 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Fairfax : Virginia Hospital Center - Arlington

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Fairfax : Inova Fairfax Hospital

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Falls Church : 1160.128.1064 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Falls Church : Inova Fairfax Hospital

CONcomitant eValuation of Epicor Left atRial Therapy for AF

Falls Church : 1160.129.32146 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Manassas : 1160.129.32200 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Norfolk : Sentara Norfolk General Hospital

ABLATE AF Registry Trial

Norfolk : Sentara Norfolk General Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Norfolk : Sentara Norfolk Hospital

Dual Epicardial Endocardial Persistent Atrial Fibrillation (AF) Study ( Staged DEEP)

Norfolk : Sentara Cardiovascular Research Institute

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Richmond : University of Virginia Commonwealth/Medical College of Virginia

ABLATE AF Registry Trial

Richmond : Otsuka Investigational Site

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

Richmond : Virginia Commonwealth University Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Richmond : Virginia Commonwealth University

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Richmond : Virginia Commonwealth University

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Washington

Burien : 1160.129.32062 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Port Orchard : 1160.129.32227 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Seattle : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Seattle : Swedish Medical Center

ABLATE AF Registry Trial

Seattle : Swedish Medical Center - Providence Campus

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

View More »

Seattle : University of Washington Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Seattle : 1160.129.32241 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Tacoma : Cardiac Study Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

West Virginia

Huntington : 1160.129.32028 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Wisconsin

Marshfield : St. Josephs Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Marshfield : Marshfield Clinical Research Foundation

Clarification of Optimal Anticoagulation Through Genetics

Milwaukee : Aurora Saint Lukes Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Milwaukee : 1160.129.32041 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Milwaukee : 1160.129.32058 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

View More »

Milwaukee : 1160.129.32088 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Milwaukee : St. Luke's Medical Center

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Wausau : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Wausau : Aspirus Wausau Hospital

ABLATE AF Registry Trial

Australia

Adelaide : Royal Adelaide Hospital

Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation

Adelaide : Royal Adelaide Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Greenslopes : Greenslopes Private Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Herston : Royal Brisbane and Women's Hospital

Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation

Parkville : Royal Adelaide Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

View More »

Parkville : Royal Melbourne Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Perth : Royal Perth Hospital

ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial

Westmead : Westmead Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Westworthville : Westmead Hospital

Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation

Woolloongabba : Princess Alexandra Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Austria

Graz : LKH/Uniklinikum - Klinische Abteilung für Kardiologie

Graz Study on the Risk of Atrial Fibrillation

Graz : Marianne Brodmann

Prospective, Multi Centre, International Registry of Male and Female Patients Newly Diagnosed With Atrial Fibrillation

Linz : KH d. Elisabethinen Linz GmbH

ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial

Linz : A. ö. Krankenhaus der Elisabethinen Linz

Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation

Many Locations :

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation

View More »

Wien : Allgemeines Krankenhaus der Stadt Wien

Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation

Belgium

Antwerpen : A.Z. Middelheim

Clinical effecT of Heart Failure Management Via Home Monitoring With a Focus on Atrial Fibrillation (effecT)

Antwerpen : AZ Middelheim

Evaluation of the Incidence of Cerebral Lesions Post Pulmonary Vein Ablation Catheter (PVAC)

Bonheiden : Imelda Ziekenhuis

Evaluation of the Incidence of Cerebral Lesions Post Pulmonary Vein Ablation Catheter (PVAC)

Brugge : A.Z. St Jan AV

Atrial Fibrillation Progression Trial

Brugge : AZ St. Jan

Clinical effecT of Heart Failure Management Via Home Monitoring With a Focus on Atrial Fibrillation (effecT)

View More »

Brugge : AZ St Jan, Cardiologie

REVOLUTION (WFCC-133)

Bruxelles : Cliniques universitaires Saint-Luc

ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial

Ghent : Drug Research Unit Ghent

A Healthy Volunteer Study to Investigate the Blood Concentrations, the Effect on Blood Clotting and the Safety of Multiple Doses of DPOC-4088 Tablets in Different Doses.

Gilly : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Leuven : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Liege : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Many Locations :

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation

MOL : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Brazil

Belo Horizonte : 1160.129.22011 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Sao Jose do Rio Preto : 1160.129.22001 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Sao Paulo : Hospital Sao Paulo

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Sao Paulo : Merck Sharp & Dohme Farmaceutica Ltda.

International Registry on Cardioversion of Atrial Fibrillation (MK-6621-051)

Votuporanga : 1160.129.22025 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Canada

Antigonish : 1160.129.06010 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Calgary : Foothills Medical Center

ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial

Calgary : University of Calgary

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Calgary : 1160.129.06018 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Calgary : University of Calgary, Foothills Hospital

Paroxysmal Atrial Fibrillation: Role of Inflammation, Oxidative Stress Injury and Effect of Statins

View More »

Cambridge : 1160.129.06023 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Chicoutimi : 1160.129.06024 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Coquitlam : 1160.129.06005 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Downsview : 1160.129.06003 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Edmonton : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Edmonton : 1160.129.06004 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Edmonton : Royal Alexandra Hospital

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Grimsby : 1160.129.06020 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Halifax : QE II Health Sciences Center

ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial

Halifax : 1160.129.06025 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Hamilton : McMaster University and Hamilton Health Sciences

ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial

Hamilton : Hamilton Health Sciences/McMaster University

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Hamilton : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Hamilton : 1160.129.06016 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Hamilton : 1160.129.06032 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Kelowna : 1160.129.06027 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Kingston : Kingston General Hospital

Incidence of Atrial Fibrillation in Patients With Severe Obstructive Sleep Apnea: The Reveal XT-SA Study

Levis : 1160.129.06014 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

London : London Health Science Centers

ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial

London : University of Western Ontario-London Health Sciences Centre

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

London : London Health Sciences Center

DAPPAR AF Dabigatran for Peri Procedural Anticoagulation During Radiofrequency Ablation of Atrial Fibrillation

MIssissauga : 1160.129.06028 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Montreal : Montreal General Hospital

ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial

Montreal : Montreal Heart Institute

ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial

Montreal : 1160.129.06009 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Montreal : Montreal Heart Institute (Institut de Cardiologie de Montreal)

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Newmarket : Southlake Regional Health Center

ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial

Newmarket : Southlake Regional Health Centre

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Newmarket : Southlake Regional Health Centre

Efficiency Study Evaluating the Use of the PVAC Catheter Technology for Performing Ablation in Patients With Atrial Fibrillation

Newmarket : Southlake Regional Health Center

Evaluation of the Incidence of Cerebral Lesions Post Pulmonary Vein Ablation Catheter (PVAC)

Oakville : 1160.129.06017 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Oshawa : 1160.129.06001 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Ottawa : Ottawa Heart Institute

ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial

Quebec : Institut universitaire de cardiologie et de pneumologie de Québec

ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial

Quebec : Institut Universitaire de Cardiologie et de Pneumologie de Québec

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Québec : 1160.129.06006 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Richmond : 1160.129.06034 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Sainte-Foy : 1160.129.06022 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Saskatoon : 1160.129.06002 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Sherbrooke : Centre hospitalier universitaire de Sherbrooke

ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial

St. John's : 1160.129.06007 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

St-Jean-sur-Richel : 1160.129.06030 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Toronto : 1160.129.06026 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Toronto : 1160.129.06029 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Toronto : 1160.129.06031 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Toronto : Sunnybrook Health Sciences Centre

Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation

Vancouver : Royal Jubilee Hospital

ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial

Vancouver : Saint Pauls Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Vancouver : St. Paul's Hospital

Measurement of Left and Right Atria From CT Scans of Cardiac Rhythm Disorder Cases

Victoria : 1160.129.06021 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program - Second and Third Phases

Victoria : Victoria Cardiac Arrhythmia Trials Inc

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

China

Beijing : Fuwai Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Beijing : Beijing Anzhen Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Beijing : 1160.114.08024 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase I)

Beijing : 1160.114.08017 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase I)

Beijing : 1160.114.08019 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase I)

View More »

Beijing : 1160.114.08018 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase I)

Beijing : 1160.114.08020 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase I)

Beijing : 1160.114.08023 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase I)

Changsha : 1160.114.08007 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase I)

Dalian : 1160.114.08021 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase I)

Ghuangzhou : 1160.114.08006 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase I)

Ghuangzhou : 1160.114.08004 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase I)

Guangzhou : Guangdong Provincial People's Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Guangzhou : 1160.114.08001 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase I)

Guangzhou : 1160.114.08002 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase I)

Guangzhou : 1160.114.08005 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase I)

Hangzhou : 1160.114.08011 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase I)

Hangzhou : 1160.114.08015 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase I)

Nanjing : First Affiliated Hospital of Nanjing Medical University

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Nanjing : 1160.114.08026 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase I)

Shanghai : 1160.114.08010 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase I)

Shanghai : 1160.114.08012 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase I)

Shanghai : 1160.114.08014 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase I)

Shanghai : 1160.114.08016 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase I)

Shanghai : 1160.114.08027 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase I)

Shenzhen : 1160.114.08028 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase I)

Tianjin : 1160.114.08022 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase I)

Wuhan : 1160.114.08008 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase I)

Czech Republic

Ceske Budejovice : Nemocnice Ceske Budejovice

Clinical effecT of Heart Failure Management Via Home Monitoring With a Focus on Atrial Fibrillation (effecT)

Olomouc : FN Olomouc

Clinical effecT of Heart Failure Management Via Home Monitoring With a Focus on Atrial Fibrillation (effecT)

Prague : Homolka Hospital

Durability of Pulmonary Vein Isolation Following Cryoablation for Treatment of Paroxysmal Atrial Fibrillation

Prague : Institute for Clinical and Experimental Medicine (IKEM)

REVOLUTION (WFCC-133)

Denmark

Copenhagen : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Hellerup : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Herning : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Many Locations :

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation

Viborg : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Estonia

Tallin : 1160.136.38001 Boehringer Ingelheim Investigational Site

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Finland

Lappeenranta : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Oulu : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Pori : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Turku : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Vaasa : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

France

Abbeville : CHG

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Antony : Hopital Privé

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Auxerre : CH

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Avignon : CH

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Bordeaux : Hôpital Cardiologique du Haut-Lévêque

ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial

View More »

Bordeaux : Clinique de Bordeaux Cauderan

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Bordeaux : HHL Hop. Haut-Lévêque

REVOLUTION (WFCC-133)

Brest : CHU de Brest

Prevention of Atrial Fibrillation by Inhibition Conversion Enzyme (ICE) After Radiofrequency Ablation of Atrial Flutter

Caen : CHU

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Castres : CH

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Clamart : HIA Percy

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Clermont Ferrand : Hôpital Gabriel Montpied

Clinical effecT of Heart Failure Management Via Home Monitoring With a Focus on Atrial Fibrillation (effecT)

Dinan : CH René Pleven

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Dole : CH

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Dunkerque : CH

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Evreux : CH

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Grenoble : CH

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Grenoble : CHU Grenoble

Cryoballoon Pulmonary Venous Isolation in Patients Referred for Typical Atrial Flutter Ablation

Grenoble : CHU de Grenoble

Prevention of Atrial Fibrillation by Inhibition Conversion Enzyme (ICE) After Radiofrequency Ablation of Atrial Flutter

Le Chesnay : CMC Parly II

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Le Havre : CH

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Lille : CHRU de Lille

Clinical effecT of Heart Failure Management Via Home Monitoring With a Focus on Atrial Fibrillation (effecT)

Lille : CHU Lille

European Carto XP Registry for Validating Specialized CFAE Software

Lille Cedex : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Limoges : CH

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Lomme : CH Saint Philibert

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Many Locations :

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation

Marseille : Hôpital La Timone

Ability of Home Monitoring® to Detect and Manage the Inappropriate Diagnoses in Implantable Cardioverter Defibrillators.

Marseille : Clinique de la Casamance

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Marseille : CHU La Timone

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Marseille : Clinique Bouchard

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Marseille : Hopital Saint Joseph

European Carto XP Registry for Validating Specialized CFAE Software

Martigues : CH

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Metz : CH

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Montpellier : CHU

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Montpellier : CHRU Hôpital de Villeneuve

Clinical effecT of Heart Failure Management Via Home Monitoring With a Focus on Atrial Fibrillation (effecT)

Montpellier : CHU Arnaud de Villeneuve

European Carto XP Registry for Validating Specialized CFAE Software

Mulhouse : CH

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Nancy : CHU Hôpital de Brabois

European Carto XP Registry for Validating Specialized CFAE Software

Nancy : HDB CHU de Nancy

REVOLUTION (WFCC-133)

Nantes : CHU Nantes

European Carto XP Registry for Validating Specialized CFAE Software

Neuilly : Ambroise Paré

European Carto XP Registry for Validating Specialized CFAE Software

Neuilly sur Seine : Clinique Ambroise Paré

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Nice : Hôpital Pasteur

Clinical effecT of Heart Failure Management Via Home Monitoring With a Focus on Atrial Fibrillation (effecT)

Nimes : Hopital Les Franciscaines

European Carto XP Registry for Validating Specialized CFAE Software

Paris : Hôpital La Pitié-Salpetrière

Clinical effecT of Heart Failure Management Via Home Monitoring With a Focus on Atrial Fibrillation (effecT)

Pessac : Hopital Cardiologique du Haut Leveque

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Pessac : CHU Haut Lévêque

Clinical effecT of Heart Failure Management Via Home Monitoring With a Focus on Atrial Fibrillation (effecT)

Quincy-sous-Sénart : Hopital Privé Claude Galien

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Rennes : Polyclinique Saint Laurent

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Rennes : CHU

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Rennes : CHU des Rennes, Hôpital de Pontchaillou

Clinical effecT of Heart Failure Management Via Home Monitoring With a Focus on Atrial Fibrillation (effecT)

Rennes : CHU de Rennes

Cryoballoon Pulmonary Venous Isolation in Patients Referred for Typical Atrial Flutter Ablation

Rennes : CHU de Rennes

Prevention of Atrial Fibrillation by Inhibition Conversion Enzyme (ICE) After Radiofrequency Ablation of Atrial Flutter

Rouen : CHU

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Rouen : University Hospital of Rouen

Cryoballoon Pulmonary Venous Isolation in Patients Referred for Typical Atrial Flutter Ablation

Rouen : CHU de Rouen

Prevention of Atrial Fibrillation by Inhibition Conversion Enzyme (ICE) After Radiofrequency Ablation of Atrial Flutter

Saint Etienne : CHU

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Saint Etienne : Hôpital Nord

Clinical effecT of Heart Failure Management Via Home Monitoring With a Focus on Atrial Fibrillation (effecT)

Saint Laurent du Var : Institut Arnalt Tzanck

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Saint-etienne : CHU de Saint-Etienne

Prevention of Atrial Fibrillation by Inhibition Conversion Enzyme (ICE) After Radiofrequency Ablation of Atrial Flutter

Schiltigheim : CMCO

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Thionville : CH

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Toulon : CH Toulon

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Toulouse : Centre Hospitalier de Rangueil

Clinical effecT of Heart Failure Management Via Home Monitoring With a Focus on Atrial Fibrillation (effecT)

Toulouse : Clinique Pasteur

Cryoballoon Pulmonary Venous Isolation in Patients Referred for Typical Atrial Flutter Ablation

Valenciennes : CH

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Germany

Aachen : Boehringer Ingelheim Investigational Site 551

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Aachen : Boehringer Ingelheim Investigational Site 552

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Aachen : Boehringer Ingelheim Investigational Site 562

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Aachen : Boehringer Ingelheim Investigational Site 563

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Aalen : Boehringer Ingelheim Investigational Site 132

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

View More »

Aalen : Boehringer Ingelheim Investigational Site 134

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Aarbergen : Boehringer Ingelheim Investigational Site 409

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ahaus : Boehringer Ingelheim Investigational Site 731

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ahaus : Boehringer Ingelheim Investigational Site 758

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ahaus : Boehringer Ingelheim Investigational Site 736

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ahaus : Boehringer Ingelheim Investigational Site 753

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ahaus-Alstaette : Boehringer Ingelheim Investigational Site 743

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ahrensburg : Boehringer Ingelheim Investigational Site 1026

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Aichtal : Boehringer Ingelheim Investigational Site 153

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Albersloh : Boehringer Ingelheim Investigational Site 797

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Albstadt : Boehringer Ingelheim Investigational Site 79

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Albstadt : Boehringer Ingelheim Investigational Site 58

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Albstadt : Boehringer Ingelheim Investigational Site 62

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Albstadt-Ebingen : Boehringer Ingelheim Investigational Site 76

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Alfeld : Boehringer Ingelheim Investigational Site 849

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Alfter : Boehringer Ingelheim Investigational Site 586

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Allenburg : Boehringer Ingelheim Investigational Site 1104

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Allersberg : Boehringer Ingelheim Investigational Site 176

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Alpenrod : Boehringer Ingelheim Investigational Site 410

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Altenburg : Boehringer Ingelheim Investigational Site 1125

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Altenburg : Boehringer Ingelheim Investigational Site 1103

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Altenholz : Boehringer Ingelheim Investigational Site 1005

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Altenholz : Boehringer Ingelheim Investigational Site 1031

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Altenstadt : Boehringer Ingelheim Investigational Site 470

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Altlussheim : Boehringer Ingelheim Investigational Site 123

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Alzenau : Boehringer Ingelheim Investigational Site 192

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Alzenau : Boehringer Ingelheim Investigational Site 189

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Alzenau : Boehringer Ingelheim Investigational Site 190

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Amberg : Boehringer Ingelheim Investigational Site 297

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Amberg : Boehringer Ingelheim Investigational Site 300

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Amberg : Boehringer Ingelheim Investigational Site 312

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Anderbeck : Boehringer Ingelheim Investigational Site 1222

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Apolda : Boehringer Ingelheim Investigational Site 1083

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Apolda : Boehringer Ingelheim Investigational Site 1091

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Arenshausen : Boehringer Ingelheim Investigational Site 1075

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Arnsberg : Boehringer Ingelheim Investigational Site 721

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Arnstadt : Boehringer Ingelheim Investigational Site 1082

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Arnstadt : Boehringer Ingelheim Investigational Site 1080

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Attendorn : Boehringer Ingelheim Investigational Site 696

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Attenkirchen : Boehringer Ingelheim Investigational Site 251

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Au am Rhein : Boehringer Ingelheim Investigational Site 7

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Aue : Boehringer Ingelheim Investigational Site 1119

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Augsburg : Boehringer Ingelheim Investigational Site 259

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Augsburg : Boehringer Ingelheim Investigational Site 279

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Augsburg : Boehringer Ingelheim Investigational Site 255

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Augsburg : Boehringer Ingelheim Investigational Site 256

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Augsburg : Boehringer Ingelheim Investigational Site 267

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Augsburg : Boehringer Ingelheim Investigational Site 278

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Babensham : Boehringer Ingelheim Investigational Site 236

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Bederkesa : Boehringer Ingelheim Investigational Site 955

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Bentheim : Boehringer Ingelheim Investigational Site 915

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Berka : Zentralklinik Bad Berka

Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation

Bad Breisig : Boehringer Ingelheim Investigational Site 415

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Driburg : Boehringer Ingelheim Investigational Site 708

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Elster : Boehringer Ingelheim Investigational Site 1124

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Ems : Boehringer Ingelheim Investigational Site 381

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Ems : Boehringer Ingelheim Investigational Site 382

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Ems : Boehringer Ingelheim Investigational Site 394

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Friedrichshall : Boehringer Ingelheim Investigational Site 114

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Homburg v.d.H. : Boehringer Ingelheim Investigational Site 458

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Homburg v.d.H. : Boehringer Ingelheim Investigational Site 459

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Homburg v.d.H. : Boehringer Ingelheim Investigational Site 460

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Klosterlausnitz : Boehringer Ingelheim Investigational Site 1107

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Kreuznach : Boehringer Ingelheim Investigational Site 385

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Krozingen : Herz-Zentrum

A Prospective Randomized Study Comparing Radiofrequency Energy With Cryoenergy

Bad Krozingen : Herz-Zentrum Bad Krozingen

ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial

Bad Krozingen : Herz-Zentrum Bad Krozingen

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Bad Krozingen : Herzzentrum Bad Krozingen, Elektrophysiologie

Ventricular Pacing Site Selection (V-PASS)

Bad Langensalza : Boehringer Ingelheim Investigational Site 1065

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Lauterberg : Boehringer Ingelheim Investigational Site 828

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Lauterberg : Boehringer Ingelheim Investigational Site 825

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Lauterberg : Boehringer Ingelheim Investigational Site 826

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Lauterberg : Boehringer Ingelheim Investigational Site 831

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Muenstereifel : Boehringer Ingelheim Investigational Site 596

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Nauheim : Kerckhoff Klinik

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Bad Nauheim : Boehringer Ingelheim Investigational Site 456

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Nauheim : Boehringer Ingelheim Investigational Site 457

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Nauheim : Boehringer Ingelheim Investigational Site 392

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Neuenahr : Boehringer Ingelheim Investigational Site 387

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Neustadt : Boehringer Ingelheim Investigational Site 188

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Neustadt/Saale : Herz- und Gefäß-Klinik

Evaluation of the Incidence of Cerebral Lesions Post Pulmonary Vein Ablation Catheter (PVAC)

Bad Neustadt/Saale : Klinik für Kardiologie II mit interventioneller Elektrophysiologie

FIRE AND ICE: Comparative Study of Two Ablation Procedures in Patients With Atrial Fibrillation

Bad Oeynhausen : Herz- und Diabeteszentrum Nordrhein-Westfalen

Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation

Bad Oeynhausen : Herz-und Diabeteszentrum NRW

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Bad Oeynhausen : Herz -und Diabeteszentrum

DEtermining Accuracy and TrEnding CharacTerization of AF

Bad Pyrmont : Boehringer Ingelheim Investigational Site 878

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Reichenhall : Boehringer Ingelheim Investigational Site 215

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Reichenhall : Boehringer Ingelheim Investigational Site 214

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Sachsa : Boehringer Ingelheim Investigational Site 830

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Sachsa : Boehringer Ingelheim Investigational Site 829

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Saeckingen : Boehringer Ingelheim Investigational Site 14

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Salzuflen : Boehringer Ingelheim Investigational Site 773

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Salzuflen : Boehringer Ingelheim Investigational Site 788

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Salzungen : Boehringer Ingelheim Investigational Site 1068

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Salzungen : Boehringer Ingelheim Investigational Site 1077

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Schussenried : Boehringer Ingelheim Investigational Site 70

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Schussenried : Boehringer Ingelheim Investigational Site 69

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Schwartau : Boehringer Ingelheim Investigational Site 1001

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Schwartau : Boehringer Ingelheim Investigational Site 982

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Sulza : Boehringer Ingelheim Investigational Site 1087

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Ueberkingen : Boehringer Ingelheim Investigational Site 83

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Waldsee : Boehringer Ingelheim Investigational Site 60

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Wiesee : Boehringer Ingelheim Investigational Site 221

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Wiessee : Boehringer Ingelheim Investigational Site 199

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Wildbad : Boehringer Ingelheim Investigational Site 50

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Badel : Boehringer Ingelheim Investigational Site 1230

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Baden-Baden : Boehringer Ingelheim Investigational Site 1

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Badenhausen : Boehringer Ingelheim Investigational Site 856

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Baindt : Boehringer Ingelheim Investigational Site 65

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Baindt : Boehringer Ingelheim Investigational Site 66

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bamberg : Boehringer Ingelheim Investigational Site 1336

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bamberg : Boehringer Ingelheim Investigational Site 1330

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Barchfeld : Boehringer Ingelheim Investigational Site 1090

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bargteheide : Boehringer Ingelheim Investigational Site 1025

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Barssel/Harkebruegge : Boehringer Ingelheim Investigational Site 911

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Baruth : Boehringer Ingelheim Investigational Site 1283

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bassum : Boehringer Ingelheim Investigational Site 864

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Baumholder : Boehringer Ingelheim Investigational Site 389

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Baumholder : Boehringer Ingelheim Investigational Site 384

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Baunatal : Boehringer Ingelheim Investigational Site 497

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bautzen : Boehringer Ingelheim Investigational Site 1286

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bayreuth : Boehringer Ingelheim Investigational Site 327

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bechhofen : Boehringer Ingelheim Investigational Site 354

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Beckum : Boehringer Ingelheim Investigational Site 781

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Beckum : Boehringer Ingelheim Investigational Site 782

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Beilrode : Boehringer Ingelheim Investigational Site 1306

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bellngries : Boehringer Ingelheim Investigational Site 183

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bendorf : Boehringer Ingelheim Investigational Site 403

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bensheim : Boehringer Ingelheim Investigational Site 446

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berg. Gladbach : Boehringer Ingelheim Investigational Site 805

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bergen : Boehringer Ingelheim Investigational Site 1056

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bergkamen-Ruenthe : Boehringer Ingelheim Investigational Site 717

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Vivantes-Klinikum am Urban

Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation

Berlin : Charité Campus Virchow-Klinikum

Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation

Berlin : Franz-Volhard-Klinik, Universitätsklinikum Charité

Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation

Berlin : Charité Campus Mitte

Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation

Berlin : Charitè Berlin

Clinical effecT of Heart Failure Management Via Home Monitoring With a Focus on Atrial Fibrillation (effecT)

Berlin : Boehringer Ingelheim Investigational Site 1256

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1232

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1237

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1239

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1240

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1243

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1160

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1162

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1133

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1136

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1137

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1138

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1141

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1165

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1166

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1167

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1172

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1175

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1176

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1177

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1178

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1179

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1182

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1184

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1185

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1186

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1187

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1255

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1257

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1238

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1241

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1242

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1244

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1191

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1193

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1134

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1135

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1127

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1128

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1161

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1163

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1168

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1171

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1174

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1181

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Berlin-Lankwitz : Boehringer Ingelheim Investigational Site 1132

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bernau : Boehringer Ingelheim Investigational Site 1164

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bernsdorf : Boehringer Ingelheim Investigational Site 1282

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Beselich-Obertiefenbach : Boehringer Ingelheim Investigational Site 397

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Beselich-Obertiefenbach : Boehringer Ingelheim Investigational Site 411

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bettingen : Boehringer Ingelheim Investigational Site 535

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Beverungen : Boehringer Ingelheim Investigational Site 726

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Biberach : Boehringer Ingelheim Investigational Site 59

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Biblis : Boehringer Ingelheim Investigational Site 441

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Biedenkopf : Boehringer Ingelheim Investigational Site 490

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Biedenkopf : Boehringer Ingelheim Investigational Site 511

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bielefeld : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Bielefeld : Städtische Kliniken Bielefeld

Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation

Bielefeld : Boehringer Ingelheim Investigational Site 798

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bielefeld : Boehringer Ingelheim Investigational Site 775

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bingen : Boehringer Ingelheim Investigational Site 75

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bischofferode : Boehringer Ingelheim Investigational Site 1073

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bischofsheim : Boehringer Ingelheim Investigational Site 434

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bismark : Boehringer Ingelheim Investigational Site 1231

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bispingen : Boehringer Ingelheim Investigational Site 966

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bitterfeld : Boehringer Ingelheim Investigational Site 1226

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Blaubeuren : Boehringer Ingelheim Investigational Site 73

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Blomberg : Boehringer Ingelheim Investigational Site 793

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bobritzsch : Boehringer Ingelheim Investigational Site 1269

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bochum : Boehringer Ingelheim Investigational Site 685

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bochum : Boehringer Ingelheim Investigational Site 686

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bochum : Boehringer Ingelheim Investigational Site 682

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bochum : Boehringer Ingelheim Investigational Site 679

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bochum : Boehringer Ingelheim Investigational Site 680

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bochum : Boehringer Ingelheim Investigational Site 677

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bochum : Boehringer Ingelheim Investigational Site 684

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bochum : Boehringer Ingelheim Investigational Site 687

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bodenkirchen : Boehringer Ingelheim Investigational Site 290

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Boeblingen : Boehringer Ingelheim Investigational Site 33

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Boehlen : Boehringer Ingelheim Investigational Site 1303

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bonn : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Bonn : St. Marien Hospital

Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation

Bonn : Saint Marien Hospital Bonn

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Bonn : Boehringer Ingelheim Investigational Site 598

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bonndorf : Boehringer Ingelheim Investigational Site 38

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bonndorf : Boehringer Ingelheim Investigational Site 29

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Boostedt : Boehringer Ingelheim Investigational Site 1013

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bopfingen : Boehringer Ingelheim Investigational Site 133

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bordesholm : Boehringer Ingelheim Investigational Site 1032

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Borgholzhausen : Boehringer Ingelheim Investigational Site 796

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Borken : Boehringer Ingelheim Investigational Site 745

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Borna : Boehringer Ingelheim Investigational Site 1319

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bottrop : Boehringer Ingelheim Investigational Site 740

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bovenden-Reyershausen : Boehringer Ingelheim Investigational Site 857

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Braeunlingen : Boehringer Ingelheim Investigational Site 37

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bramsche : Boehringer Ingelheim Investigational Site 922

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Braunsbedra : Boehringer Ingelheim Investigational Site 1302

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Braunschweig : Boehringer Ingelheim Investigational Site 835

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Braunschweig : Boehringer Ingelheim Investigational Site 834

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Braunschweig : Boehringer Ingelheim Investigational Site 837

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Braunschweig : Boehringer Ingelheim Investigational Site 843

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Breitenguessbach : Boehringer Ingelheim Investigational Site 1338

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Breke : Boehringer Ingelheim Investigational Site 908

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bremen : Zentralkrankenhaus Links der Weser, Siebels & Langes Partnerschaft

Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation

Bremen : Boehringer Ingelheim Investigational Site 944

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bremen : Boehringer Ingelheim Investigational Site 949

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bremen : Boehringer Ingelheim Investigational Site 936

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bremen : Boehringer Ingelheim Investigational Site 945

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bremen : Boehringer Ingelheim Investigational Site 946

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bremen : Boehringer Ingelheim Investigational Site 947

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bremen : Boehringer Ingelheim Investigational Site 948

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bremen : Boehringer Ingelheim Investigational Site 950

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bremerhaven : Boehringer Ingelheim Investigational Site 929

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bremerhaven : Boehringer Ingelheim Investigational Site 960

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bremerhaven : Boehringer Ingelheim Investigational Site 930

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bremerhaven : Boehringer Ingelheim Investigational Site 932

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bremervoerde : Boehringer Ingelheim Investigational Site 934

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bretten : Boehringer Ingelheim Investigational Site 120

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bruchweiler-Baerenbach : Boehringer Ingelheim Investigational Site 370

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bruck : Boehringer Ingelheim Investigational Site 313

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Buchbach : Boehringer Ingelheim Investigational Site 288

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Buchbach : Boehringer Ingelheim Investigational Site 289

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Buchholz : Boehringer Ingelheim Investigational Site 964

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Buchholz : Boehringer Ingelheim Investigational Site 935

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bueckeburg : Boehringer Ingelheim Investigational Site 863

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Burg (Spreewald) : Boehringer Ingelheim Investigational Site 1150

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Burgdorf : Boehringer Ingelheim Investigational Site 873

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Burgdorf : Boehringer Ingelheim Investigational Site 877

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Burgneudorf : Boehringer Ingelheim Investigational Site 1281

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Butzbach : Boehringer Ingelheim Investigational Site 484

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Castrop-Rauxel : Boehringer Ingelheim Investigational Site 727

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Castrop-Rauxel : Boehringer Ingelheim Investigational Site 713

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Castrop-Rauxel : Boehringer Ingelheim Investigational Site 715

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Chemnitz : Boehringer Ingelheim Investigational Site 1114

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Chemnitz : Boehringer Ingelheim Investigational Site 1115

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Chemnitz : Boehringer Ingelheim Investigational Site 1116

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Chemnitz : Boehringer Ingelheim Investigational Site 1117

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Chemnitz : Boehringer Ingelheim Investigational Site 1097

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Chemnitz : Boehringer Ingelheim Investigational Site 1098

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Chemnitz : Boehringer Ingelheim Investigational Site 1099

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Chemnitz : Boehringer Ingelheim Investigational Site 1096

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Chemnitz : Boehringer Ingelheim Investigational Site 1110

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Chemnitz : Boehringer Ingelheim Investigational Site 1113

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Coburg : Klinikum Coburg

Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation

Coburg : Klinikum Coburg

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Coburg : Boehringer Ingelheim Investigational Site 349

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Coburg : Klinikum Coburg

Mode Evaluation in Sick Sinus Syndrome Trial (MODEST)

Cochem : Boehringer Ingelheim Investigational Site 414

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Coswig : Boehringer Ingelheim Investigational Site 1210

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Cottbus : Boehringer Ingelheim Investigational Site 1148

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Crinitz : Boehringer Ingelheim Investigational Site 1152

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dachau : Boehringer Ingelheim Investigational Site 253

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Darmstadt : Boehringer Ingelheim Investigational Site 445

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dautphetal : Boehringer Ingelheim Investigational Site 520

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Deggendorf : Boehringer Ingelheim Investigational Site 304

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Delitzsch : Boehringer Ingelheim Investigational Site 1311

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Demmin : Boehringer Ingelheim Investigational Site 1055

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dessau-Rosslau : Boehringer Ingelheim Investigational Site 1212

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Detmold : Boehringer Ingelheim Investigational Site 790

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dieburg : Boehringer Ingelheim Investigational Site 454

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dieburg : Boehringer Ingelheim Investigational Site 455

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Diepenau : Boehringer Ingelheim Investigational Site 888

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Diessen : Boehringer Ingelheim Investigational Site 202

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dietzhoelztal : Boehringer Ingelheim Investigational Site 513

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dillingen/Saar : Boehringer Ingelheim Investigational Site 525

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dinkelsbuehl : Boehringer Ingelheim Investigational Site 187

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dinkelsbuehl : Boehringer Ingelheim Investigational Site 178

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dinkelsbuehl : Boehringer Ingelheim Investigational Site 165

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dinklage : Boehringer Ingelheim Investigational Site 913

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dinslaken : Boehringer Ingelheim Investigational Site 636

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dinslaken-Averbruch : Boehringer Ingelheim Investigational Site 668

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Doberan : Boehringer Ingelheim Investigational Site 1052

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Doerfles-Esbach : Boehringer Ingelheim Investigational Site 345

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dogern : Boehringer Ingelheim Investigational Site 15

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dortmund : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Dortmund : Boehringer Ingelheim Investigational Site 703

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dortmund : Boehringer Ingelheim Investigational Site 560

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dortmund : Boehringer Ingelheim Investigational Site 712

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dortmund : Boehringer Ingelheim Investigational Site 701

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dortmund : Boehringer Ingelheim Investigational Site 702

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dortmund : Boehringer Ingelheim Investigational Site 704

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dortmund : Boehringer Ingelheim Investigational Site 705

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dortmund : Boehringer Ingelheim Investigational Site 706

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dortmund : Boehringer Ingelheim Investigational Site 707

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dreieich : Boehringer Ingelheim Investigational Site 477

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dreieich : Boehringer Ingelheim Investigational Site 481

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dreieich-Dreieichenhain : Boehringer Ingelheim Investigational Site 479

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dresden : Praxisklinik Herz and Gefaesse

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Dresden : Städtisches Klinikum Dresden-Friedrichstadt

Clinical effecT of Heart Failure Management Via Home Monitoring With a Focus on Atrial Fibrillation (effecT)

Dresden : Boehringer Ingelheim Investigational Site 1278

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dresden : Boehringer Ingelheim Investigational Site 1279

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dresden : Boehringer Ingelheim Investigational Site 1275

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dresden : Boehringer Ingelheim Investigational Site 1291

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dresden : Boehringer Ingelheim Investigational Site 1292

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dresden : Boehringer Ingelheim Investigational Site 1276

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dresden : Boehringer Ingelheim Investigational Site 1280

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dresden : Boehringer Ingelheim Investigational Site 1290

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dresden : Boehringer Ingelheim Investigational Site 1259

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dresden : Boehringer Ingelheim Investigational Site 1260

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dresden : Praxisklinik - Herz- und Gefässe

Evaluation of the Incidence of Cerebral Lesions Post Pulmonary Vein Ablation Catheter (PVAC)

Driedorf : Boehringer Ingelheim Investigational Site 515

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Drochtersen : Boehringer Ingelheim Investigational Site 973

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Drochtersen : Boehringer Ingelheim Investigational Site 974

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dudenhofen : Boehringer Ingelheim Investigational Site 366

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duesseldorf : Boehringer Ingelheim Investigational Site 803

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duesseldorf : Boehringer Ingelheim Investigational Site 604

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duesseldorf : Boehringer Ingelheim Investigational Site 607

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duesseldorf : Boehringer Ingelheim Investigational Site 610

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duesseldorf : Boehringer Ingelheim Investigational Site 629

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duesseldorf : Boehringer Ingelheim Investigational Site 810

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duesseldorf : Boehringer Ingelheim Investigational Site 812

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duesseldorf : Boehringer Ingelheim Investigational Site 608

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duesseldorf : Boehringer Ingelheim Investigational Site 609

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duesseldorf : Boehringer Ingelheim Investigational Site 612

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duesseldorf : Boehringer Ingelheim Investigational Site 613

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duesseldorf : Boehringer Ingelheim Investigational Site 627

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duesseldorf : Boehringer Ingelheim Investigational Site 628

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duesseldorf (Benrath) : Boehringer Ingelheim Investigational Site 811

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duisburg : Boehringer Ingelheim Investigational Site 640

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duisburg : Boehringer Ingelheim Investigational Site 649

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duisburg : Boehringer Ingelheim Investigational Site 645

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duisburg : Boehringer Ingelheim Investigational Site 647

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duisburg : Boehringer Ingelheim Investigational Site 648

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Durach : Boehringer Ingelheim Investigational Site 197

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Düsseldorf : Evangelisches Krankenhaus Düsseldorf

Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation

Ebeleben : Boehringer Ingelheim Investigational Site 1071

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ebergoizen : Boehringer Ingelheim Investigational Site 859

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ebersburg-Schmalnau : Boehringer Ingelheim Investigational Site 507

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Eckernfoerde : Boehringer Ingelheim Investigational Site 995

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Eckernfoerde : Boehringer Ingelheim Investigational Site 985

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Edling : Boehringer Ingelheim Investigational Site 235

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Efringen-Kirchen : Boehringer Ingelheim Investigational Site 13

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ehingen : Boehringer Ingelheim Investigational Site 68

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ehrenkirchen : Boehringer Ingelheim Investigational Site 19

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ehringshausen : Boehringer Ingelheim Investigational Site 462

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Eichstaett : Boehringer Ingelheim Investigational Site 167

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Eilenburg : Boehringer Ingelheim Investigational Site 1324

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Einbeck : Boehringer Ingelheim Investigational Site 858

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Eisenhuettenstadt : Boehringer Ingelheim Investigational Site 1159

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Elsterwerda : Boehringer Ingelheim Investigational Site 1157

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Elz : Boehringer Ingelheim Investigational Site 408

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Engelskirchen-Ruenderoth : Boehringer Ingelheim Investigational Site 592

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ennigerloh-Ostenfelde : Boehringer Ingelheim Investigational Site 779

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Eppelborn : Boehringer Ingelheim Investigational Site 539

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Eppingen : Boehringer Ingelheim Investigational Site 117

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Erfde : Boehringer Ingelheim Investigational Site 1011

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Erftstadt : Boehringer Ingelheim Investigational Site 600

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Erftstadt : Boehringer Ingelheim Investigational Site 602

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Erfurt : Boehringer Ingelheim Investigational Site 1070

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Erkelenz : Boehringer Ingelheim Investigational Site 574

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Erlangen : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Erlangen : Boehringer Ingelheim Investigational Site 184

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Erlangen : Boehringer Ingelheim Investigational Site 185

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Erlangen : Boehringer Ingelheim Investigational Site 177

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Eschborn : Boehringer Ingelheim Investigational Site 461

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Eschwege : Boehringer Ingelheim Investigational Site 494

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Eschweiler : Boehringer Ingelheim Investigational Site 550

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Espelkamp : Boehringer Ingelheim Investigational Site 795

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Essen : Boehringer Ingelheim Investigational Site 659

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Essen : Boehringer Ingelheim Investigational Site 660

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Essen : Boehringer Ingelheim Investigational Site 646

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Essen : Boehringer Ingelheim Investigational Site 638

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Essen : Boehringer Ingelheim Investigational Site 637

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Essen : Boehringer Ingelheim Investigational Site 651

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Essen : Boehringer Ingelheim Investigational Site 652

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Essen : Boehringer Ingelheim Investigational Site 653

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Essen : Boehringer Ingelheim Investigational Site 654

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Essen : Boehringer Ingelheim Investigational Site 655

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Essen : Boehringer Ingelheim Investigational Site 656

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Essen : Boehringer Ingelheim Investigational Site 657

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Essen : Boehringer Ingelheim Investigational Site 658

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Essen : Universitätsklinikum Essen

DISCOVERY: Diagnostic Data and Genetic Polymorphisms in ICD Patients.

Essen : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Esslingen : Boehringer Ingelheim Investigational Site 125

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ettlingen : Boehringer Ingelheim Investigational Site 28

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Euskirchen : Boehringer Ingelheim Investigational Site 599

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Eutin : Boehringer Ingelheim Investigational Site 999

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Fassberg : Boehringer Ingelheim Investigational Site 872

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Felsberg-Gensungen : Boehringer Ingelheim Investigational Site 500

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Flensburg : Boehringer Ingelheim Investigational Site 983

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Flensburg : Boehringer Ingelheim Investigational Site 984

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Flensburg : Boehringer Ingelheim Investigational Site 986

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Flensburg : Boehringer Ingelheim Investigational Site 1007

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Flensbursg : Boehringer Ingelheim Investigational Site 1010

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Floeha : Boehringer Ingelheim Investigational Site 1264

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Florstadt / Staden : Boehringer Ingelheim Investigational Site 474

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Forchheim : Boehringer Ingelheim Investigational Site 1331

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Forchheim : Boehringer Ingelheim Investigational Site 1332

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Frankenberg : Boehringer Ingelheim Investigational Site 512

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Frankfurt : CCB - Cardioaniologisches Centrum Bethanien

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Frankfurt : Boehringer Ingelheim Investigational Site 450

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Frankfurt : Boehringer Ingelheim Investigational Site 452

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Frankfurt : Boehringer Ingelheim Investigational Site 447

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Frankfurt : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Frankfurt : Cardioangiologisches Centrum Bethanien - CCB

FIRE AND ICE: Comparative Study of Two Ablation Procedures in Patients With Atrial Fibrillation

Frankfurt (Oder) : Boehringer Ingelheim Investigational Site 1139

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Frankfurt am Main : Boehringer Ingelheim Investigational Site 475

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Frankfurt/M. : Boehringer Ingelheim Investigational Site 449

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Frankfurt/M. : Boehringer Ingelheim Investigational Site 476

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Frankfurt/Oder : Boehringer Ingelheim Investigational Site 1140

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Frankfurt/Oder : Boehringer Ingelheim Investigational Site 1131

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Frechen : Boehringer Ingelheim Investigational Site 559

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Freiberg : Boehringer Ingelheim Investigational Site 1263

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Freiberg : Boehringer Ingelheim Investigational Site 1274

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Freiburg : Boehringer Ingelheim Investigational Site 18

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Freinsheim : Boehringer Ingelheim Investigational Site 373

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Freising : Boehringer Ingelheim Investigational Site 248

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Freital : Boehringer Ingelheim Investigational Site 1271

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Fremdingen : Boehringer Ingelheim Investigational Site 168

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Frensdorf : Boehringer Ingelheim Investigational Site 329

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Friedrichshafen : Boehringer Ingelheim Investigational Site 85

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Fritzlar : Boehringer Ingelheim Investigational Site 486

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Froendenberg : Boehringer Ingelheim Investigational Site 725

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Froendenberg : Boehringer Ingelheim Investigational Site 711

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Froendenberg : Boehringer Ingelheim Investigational Site 723

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Fuerstenfeldbruck : Boehringer Ingelheim Investigational Site 293

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Fuerstenfeldbruck-Aich : Boehringer Ingelheim Investigational Site 291

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Fuerstenwalde/Spree : Boehringer Ingelheim Investigational Site 1145

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Fuerstenwalde/Spree : Boehringer Ingelheim Investigational Site 1144

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Fuerth : Boehringer Ingelheim Investigational Site 326

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Fulda : Boehringer Ingelheim Investigational Site 496

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gangkofen : Boehringer Ingelheim Investigational Site 321

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Garching : Boehringer Ingelheim Investigational Site 275

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gardelegen : Boehringer Ingelheim Investigational Site 1229

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Garmisch-Partenkirchen : Boehringer Ingelheim Investigational Site 201

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Garmisch-Patenkirchen : Boehringer Ingelheim Investigational Site 210

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gedern-Wenings : Boehringer Ingelheim Investigational Site 483

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Geeste : Boehringer Ingelheim Investigational Site 910

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Geisenkirchen-Buer : Boehringer Ingelheim Investigational Site 739

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Geislingen/Steige : Boehringer Ingelheim Investigational Site 63

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Geislingen/Steige : Boehringer Ingelheim Investigational Site 74

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gelsenkichen : Boehringer Ingelheim Investigational Site 759

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gelsenkirchen : Boehringer Ingelheim Investigational Site 762

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gelsenkirchen : Boehringer Ingelheim Investigational Site 764

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gelsenkirchen : Boehringer Ingelheim Investigational Site 765

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gelsenkirchen : Boehringer Ingelheim Investigational Site 742

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gelsenkirchen : Boehringer Ingelheim Investigational Site 744

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gelsenkirchen : Boehringer Ingelheim Investigational Site 738

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gelsenkirchen : Boehringer Ingelheim Investigational Site 763

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gensingen : Boehringer Ingelheim Investigational Site 431

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Genthin : Boehringer Ingelheim Investigational Site 1195

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Genthin : Boehringer Ingelheim Investigational Site 1194

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gera : Boehringer Ingelheim Investigational Site 1094

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gera : Boehringer Ingelheim Investigational Site 1093

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Geretsried : Boehringer Ingelheim Investigational Site 224

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Germersheim : Boehringer Ingelheim Investigational Site 359

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gersfeld : Boehringer Ingelheim Investigational Site 519

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gerstetten : Boehringer Ingelheim Investigational Site 72

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Giengen : Boehringer Ingelheim Investigational Site 61

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Giessen : Boehringer Ingelheim Investigational Site 487

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Giessen : Boehringer Ingelheim Investigational Site 488

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gifhorn : Boehringer Ingelheim Investigational Site 836

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gilching : Boehringer Ingelheim Investigational Site 209

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gluecksburg : Boehringer Ingelheim Investigational Site 1012

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Goerlitz : Boehringer Ingelheim Investigational Site 1267

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Goerlitz : Boehringer Ingelheim Investigational Site 1266

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Goertlitz : Boehringer Ingelheim Investigational Site 1288

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Goettingen : Universitätsmedizin Göttingen (UMG), Kardiologie und Pneumologie

Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion

Goettingen-Weende : Boehringer Ingelheim Investigational Site 861

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Goldberg : Boehringer Ingelheim Investigational Site 1048

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gondelsheim : Boehringer Ingelheim Investigational Site 119

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gottingen : Universitatsmedizin Gottingen Abteilung Kardiologie und

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Göttingen : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Göttingen : Universitätsklinikum Göttingen

Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation

Graefelfing : Boehringer Ingelheim Investigational Site 229

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Graefenhainichen : Boehringer Ingelheim Investigational Site 1307

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Grafenrheinfeld : Boehringer Ingelheim Investigational Site 172

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Greifswald : Universitätsklinikum der Ernst-Moritz-Arndt-Universität Greifswald

Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation

Griesheim : Boehringer Ingelheim Investigational Site 440

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Grimmen : Boehringer Ingelheim Investigational Site 1057

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Grossefehn : Boehringer Ingelheim Investigational Site 905

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gross-Groenau : Boehringer Ingelheim Investigational Site 1003

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Grossmaischeid : Boehringer Ingelheim Investigational Site 393

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gross-Zimmern : Boehringer Ingelheim Investigational Site 478

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gruenstadt : Boehringer Ingelheim Investigational Site 357

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gschwend : Boehringer Ingelheim Investigational Site 159

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Guenzburg : Boehringer Ingelheim Investigational Site 257

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Guetersloh : Boehringer Ingelheim Investigational Site 789

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Guetersloh : Boehringer Ingelheim Investigational Site 784

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Guetersloh : Boehringer Ingelheim Investigational Site 785

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gundelfingen : Boehringer Ingelheim Investigational Site 12

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Haan : Boehringer Ingelheim Investigational Site 800

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Haan : Boehringer Ingelheim Investigational Site 808

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Haar : Boehringer Ingelheim Investigational Site 233

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hachenburg : Boehringer Ingelheim Investigational Site 383

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hadamar : Boehringer Ingelheim Investigational Site 413

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hagen : Boehringer Ingelheim Investigational Site 690

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hagen : Boehringer Ingelheim Investigational Site 688

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hagen : Boehringer Ingelheim Investigational Site 689

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hagen : Boehringer Ingelheim Investigational Site 692

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hagen : Boehringer Ingelheim Investigational Site 693

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hagen : Boehringer Ingelheim Investigational Site 676

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hagen : Boehringer Ingelheim Investigational Site 669

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hagen : Boehringer Ingelheim Investigational Site 670

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Halberstadt : Boehringer Ingelheim Investigational Site 1224

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Halberstadt : Boehringer Ingelheim Investigational Site 1201

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Haldensleben : Boehringer Ingelheim Investigational Site 1205

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hallbergmoos : Boehringer Ingelheim Investigational Site 249

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Halle : Boehringer Ingelheim Investigational Site 1206

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Halle : Boehringer Ingelheim Investigational Site 1207

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Halle : Boehringer Ingelheim Investigational Site 1228

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Halle : Boehringer Ingelheim Investigational Site 1211

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Halle : Boehringer Ingelheim Investigational Site 766

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Halle : Boehringer Ingelheim Investigational Site 768

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Halle : Boehringer Ingelheim Investigational Site 780

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Halle : Boehringer Ingelheim Investigational Site 1213

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Halle : Boehringer Ingelheim Investigational Site 1208

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Halle : Boehringer Ingelheim Investigational Site 767

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Halle (Saale) : Boehringer Ingelheim Investigational Site 1214

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hallstadt : Boehringer Ingelheim Investigational Site 1337

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Hamburg : University Heart Center

ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial

Hamburg : ASKLEPIOS KLINIK St. Georg

Alster Man and Machine: Comparison of Manual and Mechanical Remote Robotic Catheter Ablation for Drug-Refractory Atrial Fibrillation

Hamburg : Asklepios Klinik St. Georg

Alster-Lost-AF-Study

Hamburg : Asklepios Klinik St. Georg

Atrial Fibrillation Management in Congestive Heart Failure With Ablation

Hamburg : University Hospital Eppendorf

CatHeter Ablation of perSistEnd Atrial Fibrillation: Pulmonary Vein Isolation Versus Defragmentation. The CHASE-AF Study

Hamburg : Asklepios Klinik Barmbek

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Hamburg : Asklepios Klinik Saint George

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Hamburg : Asklepios Klinik St. Georg

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Hamburg : Universitares Herrzentrum Hamburg

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Hamburg : Boehringer Ingelheim Investigational Site 1028

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1020

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1021

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1022

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1034

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1039

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 989

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 990

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 976

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 978

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 979

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 971

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 937

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 938

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1027

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1033

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1019

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 970

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 972

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 975

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 977

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 987

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 988

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 997

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 939

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 940

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 941

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 942

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Klinik St. Georg

European Carto XP Registry for Validating Specialized CFAE Software

Hamburg : Asklepios Klinik St. Georg

FIRE AND ICE: Comparative Study of Two Ablation Procedures in Patients With Atrial Fibrillation

Hamburg : Universitätskrankenhaus Eppendorf

Mode Evaluation in Sick Sinus Syndrome Trial (MODEST)

Hamburg-Bergstedt : Boehringer Ingelheim Investigational Site 1024

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hameln : Boehringer Ingelheim Investigational Site 879

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamm : Boehringer Ingelheim Investigational Site 724

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamm : Boehringer Ingelheim Investigational Site 719

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hammelburg : Boehringer Ingelheim Investigational Site 191

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hanau : Boehringer Ingelheim Investigational Site 473

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hanau am Main : Boehringer Ingelheim Investigational Site 469

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hanau/M. : Boehringer Ingelheim Investigational Site 471

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hannover : Boehringer Ingelheim Investigational Site 874

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hannover : Boehringer Ingelheim Investigational Site 870

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hannover : Boehringer Ingelheim Investigational Site 891

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hanstedt : Boehringer Ingelheim Investigational Site 969

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Harsewinkel : Boehringer Ingelheim Investigational Site 771

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Haseluenne : Boehringer Ingelheim Investigational Site 909

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hassloch : Boehringer Ingelheim Investigational Site 375

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hassloch : Boehringer Ingelheim Investigational Site 352

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hausham : Boehringer Ingelheim Investigational Site 205

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Havixbeck : Boehringer Ingelheim Investigational Site 748

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heddesheim : Boehringer Ingelheim Investigational Site 107

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heidelberg : Boehringer Ingelheim Investigational Site 92

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heidelberg : Boehringer Ingelheim Investigational Site 100

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heidelberg : Boehringer Ingelheim Investigational Site 105

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heidelberg : Boehringer Ingelheim Investigational Site 87

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heidelberg : Boehringer Ingelheim Investigational Site 96

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heidelberg : Department of Cardiology, University of Heidelberg

Real-Time Assessment of Cryoballoon Pulmonary Vein Isolation Using a Novel Circular Mapping Catheter

Heidelberg (Handschuhsheim) : Boehringer Ingelheim Investigational Site 106

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heidenheim : Boehringer Ingelheim Investigational Site 54

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heilbronn : Boehringer Ingelheim Investigational Site 111

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heilbronn : Boehringer Ingelheim Investigational Site 113

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heilbronn : Boehringer Ingelheim Investigational Site 110

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heilbronn : Boehringer Ingelheim Investigational Site 116

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heilbronn : Boehringer Ingelheim Investigational Site 98

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heiligenstadt : Boehringer Ingelheim Investigational Site 1074

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heilstedt : Boehringer Ingelheim Investigational Site 1221

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heimstetten : Boehringer Ingelheim Investigational Site 265

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heinsberg : Boehringer Ingelheim Investigational Site 558

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heist : Boehringer Ingelheim Investigational Site 1018

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hellenthal : Boehringer Ingelheim Investigational Site 594

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Helmstedt : Boehringer Ingelheim Investigational Site 838

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Helmstedt : Boehringer Ingelheim Investigational Site 840

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hemmoor : Boehringer Ingelheim Investigational Site 959

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hemmoor : Boehringer Ingelheim Investigational Site 953

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hemmoor : Boehringer Ingelheim Investigational Site 952

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hemmoor : Boehringer Ingelheim Investigational Site 957

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hennef : Boehringer Ingelheim Investigational Site 587

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hennef : Boehringer Ingelheim Investigational Site 584

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hennickendorf : Boehringer Ingelheim Investigational Site 1190

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Henstedt-Ulzburg : Boehringer Ingelheim Investigational Site 333

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hensted-Ulzburg : Boehringer Ingelheim Investigational Site 996

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Herford : Boehringer Ingelheim Investigational Site 776

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Herford : Boehringer Ingelheim Investigational Site 772

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Herne : Boehringer Ingelheim Investigational Site 760

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Herne : Boehringer Ingelheim Investigational Site 761

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hernhut : Boehringer Ingelheim Investigational Site 1285

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Herrenberg-Affstaett : Boehringer Ingelheim Investigational Site 42

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heubach : Boehringer Ingelheim Investigational Site 137

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heusweiler : Boehringer Ingelheim Investigational Site 541

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heusweiler : Boehringer Ingelheim Investigational Site 545

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hilden : Boehringer Ingelheim Investigational Site 799

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hildesheim : Boehringer Ingelheim Investigational Site 855

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hilpoltstein : Boehringer Ingelheim Investigational Site 181

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hirschaid : Boehringer Ingelheim Investigational Site 1333

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hirschau : Boehringer Ingelheim Investigational Site 314

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hochheim am Main : Boehringer Ingelheim Investigational Site 420

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hoechberg : Boehringer Ingelheim Investigational Site 160

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hoechberg : Boehringer Ingelheim Investigational Site 161

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hoetensleben : Boehringer Ingelheim Investigational Site 1225

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hohen Neuendorf/OT Bergfelde : Boehringer Ingelheim Investigational Site 1169

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hohenau : Boehringer Ingelheim Investigational Site 322

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hohenhameln : Boehringer Ingelheim Investigational Site 850

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hohenleipisch : Boehringer Ingelheim Investigational Site 1154

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hoisdorf : Boehringer Ingelheim Investigational Site 1023

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Holm : Boehringer Ingelheim Investigational Site 993

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hoyerswerda : Boehringer Ingelheim Investigational Site 1284

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hude/Wuesting : Boehringer Ingelheim Investigational Site 912

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hueckelhoven : Boehringer Ingelheim Investigational Site 577

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Huerth : Boehringer Ingelheim Investigational Site 585

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hummeltal : Boehringer Ingelheim Investigational Site 344

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ibbenbueren-Dickenberg : Boehringer Ingelheim Investigational Site 752

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ichenhausen : Boehringer Ingelheim Investigational Site 286

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Idar-Oberstein : Boehringer Ingelheim Investigational Site 390

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ingelheim : Boehringer Ingelheim Investigational Site 428

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ingersheim : Boehringer Ingelheim Investigational Site 115

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ingolstadt : Boehringer Ingelheim Investigational Site 163

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ingolstadt : Boehringer Ingelheim Investigational Site 179

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ingolstadt : Klinikum Ingolstadt GmbH

DEtermining Accuracy and TrEnding CharacTerization of AF

Irsch/Saar : Boehringer Ingelheim Investigational Site 546

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Iserlohn : Boehringer Ingelheim Investigational Site 694

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ismaning : Boehringer Ingelheim Investigational Site 283

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Issum : Boehringer Ingelheim Investigational Site 623

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Jahnsdorf/Erzgeb. : Boehringer Ingelheim Investigational Site 1112

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Jena : Boehringer Ingelheim Investigational Site 1092

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Jena : Boehringer Ingelheim Investigational Site 1105

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Jena-Lobeda : Boehringer Ingelheim Investigational Site 1106

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Jettingen-Unterjettingen : Boehringer Ingelheim Investigational Site 45

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Johannesberg : Boehringer Ingelheim Investigational Site 173

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Juebek : Boehringer Ingelheim Investigational Site 1009

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Juechen : Boehringer Ingelheim Investigational Site 624

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Juelich : Boehringer Ingelheim Investigational Site 548

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Juenkerath : Boehringer Ingelheim Investigational Site 531

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kaebschuetztal/OT Kroegis : Boehringer Ingelheim Investigational Site 1273

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kahl : Boehringer Ingelheim Investigational Site 171

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kaiserslautern : Boehringer Ingelheim Investigational Site 372

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kaiserslautern : Boehringer Ingelheim Investigational Site 361

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kaiserslautern : Boehringer Ingelheim Investigational Site 369

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kaiserslautern : Boehringer Ingelheim Investigational Site 362

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kaiserslautern : Boehringer Ingelheim Investigational Site 363

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kalkar : Boehringer Ingelheim Investigational Site 622

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kamen : Boehringer Ingelheim Investigational Site 718

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kamen : Boehringer Ingelheim Investigational Site 714

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kamp-Lintfort : Boehringer Ingelheim Investigational Site 666

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kappeln : Boehringer Ingelheim Investigational Site 1008

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Karlsruhe : Saint Vincentius-Kliniken

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Karlsruhe : Boehringer Ingelheim Investigational Site 11

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Karlsruhe : Boehringer Ingelheim Investigational Site 9

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Karlsruhe : Boehringer Ingelheim Investigational Site 10

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Karlsruhe : Stadtisches Klinikum Karlsruhe

European Carto XP Registry for Validating Specialized CFAE Software

Karlsruhe (Durlach) : Boehringer Ingelheim Investigational Site 8

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kassel : Boehringer Ingelheim Investigational Site 495

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kassel : Boehringer Ingelheim Investigational Site 492

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kassel : Boehringer Ingelheim Investigational Site 493

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kempen : Boehringer Ingelheim Investigational Site 617

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kempten : Boehringer Ingelheim Investigational Site 193

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kempten : Boehringer Ingelheim Investigational Site 194

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kempten : Boehringer Ingelheim Investigational Site 195

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kenzingen : Boehringer Ingelheim Investigational Site 24

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kiedrich : Boehringer Ingelheim Investigational Site 432

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kiel : Boehringer Ingelheim Investigational Site 981

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kierspe : Boehringer Ingelheim Investigational Site 698

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kippenheim : Boehringer Ingelheim Investigational Site 23

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kirchardt : Boehringer Ingelheim Investigational Site 121

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kirchardt : Boehringer Ingelheim Investigational Site 122

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kirchenlamitz : Boehringer Ingelheim Investigational Site 315

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kirchheimbolanden : Boehringer Ingelheim Investigational Site 374

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kirchheimbolanden : Boehringer Ingelheim Investigational Site 376

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kirchzarten : Boehringer Ingelheim Investigational Site 2

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kleinmachnow : Boehringer Ingelheim Investigational Site 1233

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Klettgau-Griessen : Boehringer Ingelheim Investigational Site 39

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kleve : Boehringer Ingelheim Investigational Site 616

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Klingenberg : Boehringer Ingelheim Investigational Site 170

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Klingenthal : Boehringer Ingelheim Investigational Site 1121

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 579

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 580

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 588

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 575

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 566

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 567

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 555

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 557

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 553

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 554

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 591

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 571

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 576

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 581

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln (Bilderstoeckchen) : Boehringer Ingelheim Investigational Site 568

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln-Hoehenberg : Boehringer Ingelheim Investigational Site 593

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln-Junkersdorf : Boehringer Ingelheim Investigational Site 556

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln-Lindenthal : Boehringer Ingelheim Investigational Site 570

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koenigsbrueck : Boehringer Ingelheim Investigational Site 1261

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koenigsbrunn : Boehringer Ingelheim Investigational Site 285

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koethen : Boehringer Ingelheim Investigational Site 1227

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koethen : Boehringer Ingelheim Investigational Site 1197

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Konstanz : Herz-Zentrum-Bodensee Konstanz

FIRE AND ICE: Comparative Study of Two Ablation Procedures in Patients With Atrial Fibrillation

Korschenbroich : Boehringer Ingelheim Investigational Site 626

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Krefeld : Boehringer Ingelheim Investigational Site 618

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Krefeld : Boehringer Ingelheim Investigational Site 606

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Krefeld : Boehringer Ingelheim Investigational Site 611

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Krefeld : Boehringer Ingelheim Investigational Site 621

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kreuztal : Boehringer Ingelheim Investigational Site 675

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kronach : Boehringer Ingelheim Investigational Site 341

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kronberg/Ts : Boehringer Ingelheim Investigational Site 465

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kronberg/Ts. : Boehringer Ingelheim Investigational Site 466

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kronshagen : Boehringer Ingelheim Investigational Site 1029

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kronshagen : Boehringer Ingelheim Investigational Site 1030

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Krumbach : Boehringer Ingelheim Investigational Site 277

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kuenzing : Boehringer Ingelheim Investigational Site 303

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Laaber : Boehringer Ingelheim Investigational Site 317

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Laatzen : Boehringer Ingelheim Investigational Site 893

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Laboe : Boehringer Ingelheim Investigational Site 1002

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lahnau : Boehringer Ingelheim Investigational Site 468

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Laichingen : Boehringer Ingelheim Investigational Site 71

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lalendorf : Boehringer Ingelheim Investigational Site 1053

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lampertheim : Boehringer Ingelheim Investigational Site 439

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lampertheim : Boehringer Ingelheim Investigational Site 425

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lampertheim : Boehringer Ingelheim Investigational Site 443

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Landau : Boehringer Ingelheim Investigational Site 358

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Landshut : Krankenhaus Landshut-Achdorf

Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation

Landshut : Boehringer Ingelheim Investigational Site 274

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Langenfeld : Boehringer Ingelheim Investigational Site 809

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Langenhagen : Boehringer Ingelheim Investigational Site 890

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Langenlonsheim : Boehringer Ingelheim Investigational Site 407

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lauenburg : Boehringer Ingelheim Investigational Site 1035

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lauscha : Boehringer Ingelheim Investigational Site 1079

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lauterbach : Boehringer Ingelheim Investigational Site 510

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lebus : Boehringer Ingelheim Investigational Site 1188

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leck : Boehringer Ingelheim Investigational Site 1006

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lehrte : Boehringer Ingelheim Investigational Site 875

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leiblfing : Boehringer Ingelheim Investigational Site 216

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leinfelden-Echterdingen : Boehringer Ingelheim Investigational Site 31

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leipheim : Boehringer Ingelheim Investigational Site 281

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leipzig : Herzzentrum Leipzig

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Leipzig : Boehringer Ingelheim Investigational Site 1315

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leipzig : Boehringer Ingelheim Investigational Site 1301

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leipzig : Boehringer Ingelheim Investigational Site 1308

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leipzig : Boehringer Ingelheim Investigational Site 1309

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leipzig : Boehringer Ingelheim Investigational Site 1310

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leipzig : Boehringer Ingelheim Investigational Site 1312

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leipzig : Boehringer Ingelheim Investigational Site 1304

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leipzig : Herzzentrum Leipzig GmbH

Ventricular Wall Motion Characterization

Lemwerder : Boehringer Ingelheim Investigational Site 907

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lengede-Woltwiesche : Boehringer Ingelheim Investigational Site 851

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lengerich : Boehringer Ingelheim Investigational Site 737

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lengerich : Boehringer Ingelheim Investigational Site 732

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leverkusen : Boehringer Ingelheim Investigational Site 807

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leverkusen : Boehringer Ingelheim Investigational Site 813

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leverkusen : Boehringer Ingelheim Investigational Site 814

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lichtenfels : Boehringer Ingelheim Investigational Site 346

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lichtentanne : Boehringer Ingelheim Investigational Site 1108

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Liebenau : Boehringer Ingelheim Investigational Site 504

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lienen-Kattenvenne : Boehringer Ingelheim Investigational Site 734

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lienen-Kattenvenne : Boehringer Ingelheim Investigational Site 735

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lienen-Kattenvenne : Boehringer Ingelheim Investigational Site 749

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lilienthal : Boehringer Ingelheim Investigational Site 931

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Limburgerhof : Boehringer Ingelheim Investigational Site 368

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Limburgerhof : Boehringer Ingelheim Investigational Site 364

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lindhorst : Boehringer Ingelheim Investigational Site 869

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lindlar : Boehringer Ingelheim Investigational Site 582

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lindlar : Boehringer Ingelheim Investigational Site 583

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Linnich : Boehringer Ingelheim Investigational Site 572

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Listerwerda : Boehringer Ingelheim Investigational Site 1130

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Loerrach : Boehringer Ingelheim Investigational Site 4

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lohfelden : Boehringer Ingelheim Investigational Site 501

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lohne : Boehringer Ingelheim Investigational Site 914

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lollar : Boehringer Ingelheim Investigational Site 516

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lu.-Ruchheim : Boehringer Ingelheim Investigational Site 379

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lucka : Boehringer Ingelheim Investigational Site 1126

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Luckau : Boehringer Ingelheim Investigational Site 1146

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Luckenwalde : Boehringer Ingelheim Investigational Site 1253

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ludwigsburg : Boehringer Ingelheim Investigational Site 148

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ludwigsburg : Boehringer Ingelheim Investigational Site 140

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ludwigsburg : Boehringer Ingelheim Investigational Site 147

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ludwigsburg : Boehringer Ingelheim Investigational Site 149

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ludwigsburg : Boehringer Ingelheim Investigational Site 156

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ludwigsburg : Boehringer Ingelheim Investigational Site 126

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ludwigshafen : Boehringer Ingelheim Investigational Site 365

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ludwigshafen : Boehringer Ingelheim Investigational Site 356

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ludwigslust : Boehringer Ingelheim Investigational Site 1043

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Luebben : Boehringer Ingelheim Investigational Site 1147

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Luebbenau : Boehringer Ingelheim Investigational Site 1153

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Luebeck : Boehringer Ingelheim Investigational Site 980

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Luebeck : Boehringer Ingelheim Investigational Site 998

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Luedenscheid : Boehringer Ingelheim Investigational Site 695

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Luedenscheid : Boehringer Ingelheim Investigational Site 700

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Luedenscheid : Boehringer Ingelheim Investigational Site 699

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lueneburg : Boehringer Ingelheim Investigational Site 965

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lueneburg : Boehringer Ingelheim Investigational Site 961

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lueneburg : Boehringer Ingelheim Investigational Site 963

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Luetzen : Boehringer Ingelheim Investigational Site 1322

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Luetzow : Boehringer Ingelheim Investigational Site 1046

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lutherstadt Wittenberg : Boehringer Ingelheim Investigational Site 1305

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lutzerath : Boehringer Ingelheim Investigational Site 388

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Maerkische Heide/Gross Leuthen : Boehringer Ingelheim Investigational Site 1158

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Magdeburg : Boehringer Ingelheim Investigational Site 1202

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Magdeburg : Boehringer Ingelheim Investigational Site 1196

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Magdeburg : Boehringer Ingelheim Investigational Site 1203

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Magdeburg : University Hospital Magdeburg; Div. of Cardiology

Irbesartan and Adhesion Molecules in AF

Mainaschaff : Boehringer Ingelheim Investigational Site 174

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mainz : Boehringer Ingelheim Investigational Site 426

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mainz : Boehringer Ingelheim Investigational Site 427

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mainz : Boehringer Ingelheim Investigational Site 418

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mainz : Boehringer Ingelheim Investigational Site 419

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mainz : Boehringer Ingelheim Investigational Site 422

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mainz : Boehringer Ingelheim Investigational Site 424

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Malterdingen : Boehringer Ingelheim Investigational Site 25

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mannheim : University Hospital of Mannheim

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Mannheim : Boehringer Ingelheim Investigational Site 104

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mannheim : Boehringer Ingelheim Investigational Site 102

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mannheim : Boehringer Ingelheim Investigational Site 99

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mannheim : Boehringer Ingelheim Investigational Site 94

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mannheim : Boehringer Ingelheim Investigational Site 95

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mannheim : Boehringer Ingelheim Investigational Site 91

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mannheim (Almenhof) : Boehringer Ingelheim Investigational Site 101

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mannheim (Kaefertal) : Boehringer Ingelheim Investigational Site 109

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mannheim (Neuostheim) : Boehringer Ingelheim Investigational Site 108

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mannheim (Waldhof) : Boehringer Ingelheim Investigational Site 103

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Many Locations :

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation

Marburg : Boehringer Ingelheim Investigational Site 489

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Markkleeberg : Boehringer Ingelheim Investigational Site 1321

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Markkleeberg : Boehringer Ingelheim Investigational Site 1299

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Markkleeberg : Boehringer Ingelheim Investigational Site 1300

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Markneukirchen : Boehringer Ingelheim Investigational Site 1123

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Marktleugast : Boehringer Ingelheim Investigational Site 342

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Marktredwitz : Boehringer Ingelheim Investigational Site 295

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Marl : Boehringer Ingelheim Investigational Site 754

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Meckenheim : Boehringer Ingelheim Investigational Site 378

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Meeder : Boehringer Ingelheim Investigational Site 350

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Meerbusch : Boehringer Ingelheim Investigational Site 625

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Meerbusch : Boehringer Ingelheim Investigational Site 605

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Meinerzhagen : Boehringer Ingelheim Investigational Site 697

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Meiningen : Boehringer Ingelheim Investigational Site 1089

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Meissen : Boehringer Ingelheim Investigational Site 1294

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Meissen : Boehringer Ingelheim Investigational Site 1270

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Melle : Boehringer Ingelheim Investigational Site 917

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Melle : Boehringer Ingelheim Investigational Site 918

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Melsungen : Boehringer Ingelheim Investigational Site 485

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Memmelsdorf-Drosendorf : Boehringer Ingelheim Investigational Site 330

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Memmelsdorf-Drosendorf : Boehringer Ingelheim Investigational Site 1329

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Menden : Boehringer Ingelheim Investigational Site 691

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mendig : Boehringer Ingelheim Investigational Site 402

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Merseburg : Boehringer Ingelheim Investigational Site 1296

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Messkirch : Boehringer Ingelheim Investigational Site 77

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mettingen : Boehringer Ingelheim Investigational Site 751

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Metzingen : Boehringer Ingelheim Investigational Site 53

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Michelsneukirchen : Boehringer Ingelheim Investigational Site 305

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Milower Land : Boehringer Ingelheim Investigational Site 1247

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Milower Land : Boehringer Ingelheim Investigational Site 1248

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Minden : Boehringer Ingelheim Investigational Site 774

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Minden : Boehringer Ingelheim Investigational Site 794

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Minden : Boehringer Ingelheim Investigational Site 777

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Minden : Boehringer Ingelheim Investigational Site 786

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Minden : Boehringer Ingelheim Investigational Site 787

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mittweida : Boehringer Ingelheim Investigational Site 1295

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Moenchengladbach : Boehringer Ingelheim Investigational Site 614

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Moenchengladbach : Boehringer Ingelheim Investigational Site 631

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Moenchengladbach : Boehringer Ingelheim Investigational Site 633

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Moenchengladbach : Boehringer Ingelheim Investigational Site 630

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Moenchengladbach : Boehringer Ingelheim Investigational Site 632

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Moers : Boehringer Ingelheim Investigational Site 667

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Moers : Boehringer Ingelheim Investigational Site 644

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Moers : Boehringer Ingelheim Investigational Site 641

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Moessingen : Boehringer Ingelheim Investigational Site 32

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Molfsee : Boehringer Ingelheim Investigational Site 1014

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mönchengladbach : Updated

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Moommerland : Boehringer Ingelheim Investigational Site 906

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Moormerland : Boehringer Ingelheim Investigational Site 902

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mosbach : Boehringer Ingelheim Investigational Site 89

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mosbach : Boehringer Ingelheim Investigational Site 90

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muehldorf : Boehringer Ingelheim Investigational Site 243

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muehldorf : Boehringer Ingelheim Investigational Site 266

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muehlhausen : Boehringer Ingelheim Investigational Site 1066

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muehlhausen : Boehringer Ingelheim Investigational Site 1076

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muelheim : Boehringer Ingelheim Investigational Site 665

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muelheim : Boehringer Ingelheim Investigational Site 663

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muelheim : Boehringer Ingelheim Investigational Site 661

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchberg : Boehringer Ingelheim Investigational Site 347

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 268

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 270

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 271

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 272

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 273

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 240

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 262

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 263

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 264

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 250

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 252

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 222

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 220

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 238

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 226

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 227

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 247

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 206

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 207

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 244

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 245

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 246

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 239

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 242

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 223

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 225

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenchen : Boehringer Ingelheim Investigational Site 284

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Muenster : Boehringer Ingelheim Investigational Site 769

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

München : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Munderkingen : Boehringer Ingelheim Investigational Site 64

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Munich : Deutsches Herzzentrum Muenchen

ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial

Munich : Isar Zentrum

Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation

Munich : Isar Heart Center

DEtermining Accuracy and TrEnding CharacTerization of AF

Murrhardt : Boehringer Ingelheim Investigational Site 155

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nalbach : Boehringer Ingelheim Investigational Site 544

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nassau : Boehringer Ingelheim Investigational Site 412

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nauenstadt : Boehringer Ingelheim Investigational Site 135

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nbg. : Boehringer Ingelheim Investigational Site 328

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nersingen : Boehringer Ingelheim Investigational Site 261

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nersingen : Boehringer Ingelheim Investigational Site 260

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nettersheim : Boehringer Ingelheim Investigational Site 603

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nettersheim : Boehringer Ingelheim Investigational Site 595

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nettetal : Boehringer Ingelheim Investigational Site 619

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neubiberg : Boehringer Ingelheim Investigational Site 198

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neuburg : Boehringer Ingelheim Investigational Site 162

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neuburg : Boehringer Ingelheim Investigational Site 182

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neudenau : Boehringer Ingelheim Investigational Site 157

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neuhausen ob Eck : Boehringer Ingelheim Investigational Site 40

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neuhof : Boehringer Ingelheim Investigational Site 506

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neukirchen Hl. Blut : Boehringer Ingelheim Investigational Site 308

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neumuenster : Boehringer Ingelheim Investigational Site 1015

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neumuenster : Boehringer Ingelheim Investigational Site 1016

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neunkirchen : Boehringer Ingelheim Investigational Site 521

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neuried : Boehringer Ingelheim Investigational Site 208

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neuruppin : Boehringer Ingelheim Investigational Site 1251

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neuss : Boehringer Ingelheim Investigational Site 634

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neuss-Holzheim : Boehringer Ingelheim Investigational Site 635

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neustadt : Boehringer Ingelheim Investigational Site 509

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neustadt : Boehringer Ingelheim Investigational Site 868

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neustadt : Boehringer Ingelheim Investigational Site 994

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neustadt : Boehringer Ingelheim Investigational Site 508

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neustadt/Weinstrasse : Boehringer Ingelheim Investigational Site 353

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neutraubling : Boehringer Ingelheim Investigational Site 319

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neu-Ulm : Boehringer Ingelheim Investigational Site 280

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neu-Ulm : Boehringer Ingelheim Investigational Site 282

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Neuwied : Boehringer Ingelheim Investigational Site 391

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Niederkassel-Rheidt : Boehringer Ingelheim Investigational Site 590

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Niedernwoehren : Boehringer Ingelheim Investigational Site 881

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Niederwoerresbach : Boehringer Ingelheim Investigational Site 405

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nienburg : Boehringer Ingelheim Investigational Site 884

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Noerdlingen : Boehringer Ingelheim Investigational Site 180

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Norderstedt : Boehringer Ingelheim Investigational Site 1038

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Norderstedt : Boehringer Ingelheim Investigational Site 1037

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nordheim : Boehringer Ingelheim Investigational Site 112

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nordwalde : Boehringer Ingelheim Investigational Site 746

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Northeim : Boehringer Ingelheim Investigational Site 827

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nossen : Boehringer Ingelheim Investigational Site 1258

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nossen : Boehringer Ingelheim Investigational Site 1272

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nuernberg : Boehringer Ingelheim Investigational Site 1325

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nuernberg : Boehringer Ingelheim Investigational Site 334

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nuernberg : Boehringer Ingelheim Investigational Site 335

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nuernberg : Boehringer Ingelheim Investigational Site 324

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nuernberg : Boehringer Ingelheim Investigational Site 325

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nuernberg : Boehringer Ingelheim Investigational Site 1326

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nuernberg : Boehringer Ingelheim Investigational Site 331

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nuernberg : Boehringer Ingelheim Investigational Site 336

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nuernberg : Boehringer Ingelheim Investigational Site 338

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nuernberg : Boehringer Ingelheim Investigational Site 339

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nuernberg : Boehringer Ingelheim Investigational Site 340

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Nuertingen : Boehringer Ingelheim Investigational Site 145

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Oberdorla : Boehringer Ingelheim Investigational Site 1064

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Oberhausen : Boehringer Ingelheim Investigational Site 639

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Oberhausen : Boehringer Ingelheim Investigational Site 642

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Oberhausen : Boehringer Ingelheim Investigational Site 643

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Oberhausen : Boehringer Ingelheim Investigational Site 662

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Oberhausen : Boehringer Ingelheim Investigational Site 664

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Obernkirchen : Boehringer Ingelheim Investigational Site 880

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ober-Ramstadt : Boehringer Ingelheim Investigational Site 438

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Oberried : Boehringer Ingelheim Investigational Site 3

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Obertshausen-Hausen : Boehringer Ingelheim Investigational Site 482

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Oelde : Boehringer Ingelheim Investigational Site 783

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Oerel : Boehringer Ingelheim Investigational Site 951

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Oerel : Boehringer Ingelheim Investigational Site 954

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Oer-Erkenschwich : Boehringer Ingelheim Investigational Site 716

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Oettingen : Boehringer Ingelheim Investigational Site 287

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Offenbach : Boehringer Ingelheim Investigational Site 453

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Offenburg : Boehringer Ingelheim Investigational Site 21

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Olching/Neu-Esting : Boehringer Ingelheim Investigational Site 269

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Oldenburg : Boehringer Ingelheim Investigational Site 898

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Oranienburg : Boehringer Ingelheim Investigational Site 1170

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Oranienburg : Boehringer Ingelheim Investigational Site 1180

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Oranienburg : Boehringer Ingelheim Investigational Site 1183

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Oschatz : Boehringer Ingelheim Investigational Site 1320

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Oschersleben : Boehringer Ingelheim Investigational Site 1198

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Oschersleben : Boehringer Ingelheim Investigational Site 1218

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Osloss : Boehringer Ingelheim Investigational Site 845

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Osloss : Boehringer Ingelheim Investigational Site 846

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ostercappeln : Boehringer Ingelheim Investigational Site 894

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Osterode : Boehringer Ingelheim Investigational Site 860

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ostrach : Boehringer Ingelheim Investigational Site 67

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ostseeheilbad Zingst : Boehringer Ingelheim Investigational Site 1060

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ottendorf : Boehringer Ingelheim Investigational Site 958

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Otterbach : Boehringer Ingelheim Investigational Site 371

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Otterstadt : Boehringer Ingelheim Investigational Site 367

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ottobrunn : Boehringer Ingelheim Investigational Site 203

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ottobrunn : Boehringer Ingelheim Investigational Site 218

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Paderborn : St. Vincenz-Krankenhaus

Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation

Paderborn : Boehringer Ingelheim Investigational Site 710

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Paderborn : Boehringer Ingelheim Investigational Site 728

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Paderborn : Boehringer Ingelheim Investigational Site 709

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Papenburg : Boehringer Ingelheim Investigational Site 895

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Papenburg : Boehringer Ingelheim Investigational Site 924

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Papenburg : Boehringer Ingelheim Investigational Site 923

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Papenburg : Boehringer Ingelheim Investigational Site 896

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Papenburg : Boehringer Ingelheim Investigational Site 897

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Papenburg : Kardiologische Gemeinschaftspraxis

Mode Evaluation in Sick Sinus Syndrome Trial (MODEST)

Parchim : Boehringer Ingelheim Investigational Site 1045

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Passau : Boehringer Ingelheim Investigational Site 323

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Passau : Boehringer Ingelheim Investigational Site 299

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Peine : Boehringer Ingelheim Investigational Site 844

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Peine : Boehringer Ingelheim Investigational Site 832

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Peine : Boehringer Ingelheim Investigational Site 833

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Penzberg : Boehringer Ingelheim Investigational Site 228

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Penzberg : Boehringer Ingelheim Investigational Site 204

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Pforzheim : Boehringer Ingelheim Investigational Site 124

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Pforzheim : Boehringer Ingelheim Investigational Site 34

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Pforzheim : Boehringer Ingelheim Investigational Site 35

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Pfullingen : Boehringer Ingelheim Investigational Site 78

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Pfungstadt : Boehringer Ingelheim Investigational Site 442

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Pima : Boehringer Ingelheim Investigational Site 1265

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Pirmasens : Boehringer Ingelheim Investigational Site 355

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Plaidt : Boehringer Ingelheim Investigational Site 404

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Planegg : Boehringer Ingelheim Investigational Site 232

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Plattling : Boehringer Ingelheim Investigational Site 301

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Plauen : Boehringer Ingelheim Investigational Site 1122

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Plauen : Boehringer Ingelheim Investigational Site 1111

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Plauen : Boehringer Ingelheim Investigational Site 1095

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Pleiskirchen : Boehringer Ingelheim Investigational Site 276

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ploen : Boehringer Ingelheim Investigational Site 992

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Pocking : Boehringer Ingelheim Investigational Site 320

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Poecking : Boehringer Ingelheim Investigational Site 230

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Polch : Boehringer Ingelheim Investigational Site 401

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Postdam : Boehringer Ingelheim Investigational Site 1246

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Potsdam : Boehringer Ingelheim Investigational Site 1236

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Potsdam : Boehringer Ingelheim Investigational Site 1234

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Potsdam : Boehringer Ingelheim Investigational Site 1235

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Pottenstein : Boehringer Ingelheim Investigational Site 348

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Preetz : Boehringer Ingelheim Investigational Site 1000

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Preetz : Boehringer Ingelheim Investigational Site 991

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Premnitz : Boehringer Ingelheim Investigational Site 1249

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Prerow : Boehringer Ingelheim Investigational Site 1061

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Puettlingen : Boehringer Ingelheim Investigational Site 522

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Puettlingen : Boehringer Ingelheim Investigational Site 527

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Pulheim-Brauweiler : Boehringer Ingelheim Investigational Site 569

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Pullach : Boehringer Ingelheim Investigational Site 231

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Pulsnitz : Boehringer Ingelheim Investigational Site 1287

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Querfurt : Boehringer Ingelheim Investigational Site 1313

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rabenau-Londorf : Boehringer Ingelheim Investigational Site 517

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rabitz-Rosenthal : Boehringer Ingelheim Investigational Site 1289

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Radeberg : Boehringer Ingelheim Investigational Site 1277

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Radebeul : Boehringer Ingelheim Investigational Site 1262

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Radevormwald : Boehringer Ingelheim Investigational Site 806

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rastatt-Wintersdorf : Boehringer Ingelheim Investigational Site 6

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Raubach : Boehringer Ingelheim Investigational Site 380

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ravensburg : Boehringer Ingelheim Investigational Site 86

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Recke : Boehringer Ingelheim Investigational Site 750

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Recke : Boehringer Ingelheim Investigational Site 733

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Recklinghausen : Boehringer Ingelheim Investigational Site 741

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Regensburg : Boehringer Ingelheim Investigational Site 296

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Regensburg : Boehringer Ingelheim Investigational Site 294

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Regensburg : Boehringer Ingelheim Investigational Site 318

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Remscheid : Boehringer Ingelheim Investigational Site 823

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Remscheid : Boehringer Ingelheim Investigational Site 824

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Remseck : Boehringer Ingelheim Investigational Site 141

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Remseck-Aldingen : Boehringer Ingelheim Investigational Site 143

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rennerod : Boehringer Ingelheim Investigational Site 395

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Reutlingen : Boehringer Ingelheim Investigational Site 127

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Reutlingen : Boehringer Ingelheim Investigational Site 128

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Reutlingen : Boehringer Ingelheim Investigational Site 144

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Reutlingen : Boehringer Ingelheim Investigational Site 146

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Reutlingen : Boehringer Ingelheim Investigational Site 129

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rheinberg : Boehringer Ingelheim Investigational Site 650

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rheinmuenster-Schwarzach : Boehringer Ingelheim Investigational Site 27

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rheinstetten : Boehringer Ingelheim Investigational Site 5

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rieden : Boehringer Ingelheim Investigational Site 416

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rieschweiler : Boehringer Ingelheim Investigational Site 377

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rietberg-Neuenkirchen : Boehringer Ingelheim Investigational Site 791

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rittmarshausen : Boehringer Ingelheim Investigational Site 862

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rodewisch : Boehringer Ingelheim Investigational Site 1120

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Roecknitz : Boehringer Ingelheim Investigational Site 1323

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Roederland-Proesen : Boehringer Ingelheim Investigational Site 1155

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Roedermark : Boehringer Ingelheim Investigational Site 480

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rohrberg : Boehringer Ingelheim Investigational Site 1204

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rosenheim : Boehringer Ingelheim Investigational Site 211

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rosenheim : Boehringer Ingelheim Investigational Site 213

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rosenheim : Boehringer Ingelheim Investigational Site 219

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rostock : University of Rostock

BioMonitor Master Study

Rostock : Universitätsklinikum Rostock

Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation

Rostock : Universitat Rostock

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Rostock : Boehringer Ingelheim Investigational Site 1041

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rostock : Boehringer Ingelheim Investigational Site 1051

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rotenburg : Boehringer Ingelheim Investigational Site 505

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rotenburg : Boehringer Ingelheim Investigational Site 943

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rottach-Weissach : Boehringer Ingelheim Investigational Site 200

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rudersberg : Boehringer Ingelheim Investigational Site 139

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Rudersdorf : Boehringer Ingelheim Investigational Site 1192

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ruppichteroth : Boehringer Ingelheim Investigational Site 589

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Saarbruecken : Boehringer Ingelheim Investigational Site 543

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Saarbruecken : Boehringer Ingelheim Investigational Site 542

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Saarbruecken : Boehringer Ingelheim Investigational Site 540

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Saarlouis : Boehringer Ingelheim Investigational Site 524

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Salching : Boehringer Ingelheim Investigational Site 217

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Salzatal : Boehringer Ingelheim Investigational Site 1199

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Salzatal : Boehringer Ingelheim Investigational Site 1200

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Salzatal/OT Schiepzig : Boehringer Ingelheim Investigational Site 1209

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Salzbergen : Boehringer Ingelheim Investigational Site 920

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Salzgitter (Lebenstedt) : Boehringer Ingelheim Investigational Site 852

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Salzgitter (Lebenstedt) : Boehringer Ingelheim Investigational Site 854

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Salzmuende : Boehringer Ingelheim Investigational Site 1215

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Salzmuende : Boehringer Ingelheim Investigational Site 1216

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Salzweg bei Passau : Boehringer Ingelheim Investigational Site 298

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Sandesneben : Boehringer Ingelheim Investigational Site 1036

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Sarstedt : Boehringer Ingelheim Investigational Site 853

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schenefeld : Boehringer Ingelheim Investigational Site 351

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schlagsdorf : Boehringer Ingelheim Investigational Site 1063

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schleching : Boehringer Ingelheim Investigational Site 234

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schloss Holte-Stukenbrock : Boehringer Ingelheim Investigational Site 792

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schlotheim : Boehringer Ingelheim Investigational Site 1088

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schmalkalden : Boehringer Ingelheim Investigational Site 1078

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schmelz : Boehringer Ingelheim Investigational Site 523

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schneeberg : Boehringer Ingelheim Investigational Site 1118

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schoemberg : Boehringer Ingelheim Investigational Site 51

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schoenbeck : Boehringer Ingelheim Investigational Site 1217

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schoenberg : Boehringer Ingelheim Investigational Site 1004

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schoenberg/Meckl. : Boehringer Ingelheim Investigational Site 1062

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schoensee : Boehringer Ingelheim Investigational Site 311

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schoeppenstadt : Boehringer Ingelheim Investigational Site 842

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schopfheim : Boehringer Ingelheim Investigational Site 20

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schopfheim : Boehringer Ingelheim Investigational Site 17

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schorndorf : Boehringer Ingelheim Investigational Site 138

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schorndorf : Boehringer Ingelheim Investigational Site 150

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schortens : Boehringer Ingelheim Investigational Site 899

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schramberg-Sulgen : Boehringer Ingelheim Investigational Site 43

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schutterwald : Boehringer Ingelheim Investigational Site 22

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schwabhausen : Boehringer Ingelheim Investigational Site 292

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schwaebisch Hall : Boehringer Ingelheim Investigational Site 130

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schwarzenbach a. Wald : Boehringer Ingelheim Investigational Site 343

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schwarzenbruck : Boehringer Ingelheim Investigational Site 1327

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schwerin : Boehringer Ingelheim Investigational Site 1040

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schwerin : Boehringer Ingelheim Investigational Site 1042

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schwerin : Boehringer Ingelheim Investigational Site 1058

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Schwieberdingen : Boehringer Ingelheim Investigational Site 49

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Seeg : Boehringer Ingelheim Investigational Site 196

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Seelow : Boehringer Ingelheim Investigational Site 1189

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Sehnde : Boehringer Ingelheim Investigational Site 892

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Sendenhorst : Boehringer Ingelheim Investigational Site 778

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Siegen : Boehringer Ingelheim Investigational Site 671

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Siegen : Boehringer Ingelheim Investigational Site 672

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Siegen : Boehringer Ingelheim Investigational Site 673

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Siegen : Boehringer Ingelheim Investigational Site 674

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Simmerath : Boehringer Ingelheim Investigational Site 549

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Simmertal : Boehringer Ingelheim Investigational Site 406

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Singen : Boehringer Ingelheim Investigational Site 36

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Soehrewald : Boehringer Ingelheim Investigational Site 498

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Soest : Boehringer Ingelheim Investigational Site 722

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Solingen : Boehringer Ingelheim Investigational Site 817

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Solingen : Boehringer Ingelheim Investigational Site 815

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Solingen : Boehringer Ingelheim Investigational Site 816

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Solingen : Boehringer Ingelheim Investigational Site 801

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Solingen : Boehringer Ingelheim Investigational Site 802

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Solms : Boehringer Ingelheim Investigational Site 464

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Soltau : Boehringer Ingelheim Investigational Site 968

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Soltau : Boehringer Ingelheim Investigational Site 933

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Sondershausen : Boehringer Ingelheim Investigational Site 1072

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Sondershausen : Boehringer Ingelheim Investigational Site 1084

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Sondershausen : Boehringer Ingelheim Investigational Site 1069

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Sonnenstein : Boehringer Ingelheim Investigational Site 1085

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Sonsbeck : Boehringer Ingelheim Investigational Site 620

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Spardorf : Boehringer Ingelheim Investigational Site 175

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Spardorf : Boehringer Ingelheim Investigational Site 186

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Speicher : Boehringer Ingelheim Investigational Site 533

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Spiesen-Elversberg : Boehringer Ingelheim Investigational Site 536

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Spiesen-Elversberg : Boehringer Ingelheim Investigational Site 537

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Spremberg : Boehringer Ingelheim Investigational Site 1156

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

St. Blasien : Boehringer Ingelheim Investigational Site 26

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

St. Leon-Rot : Boehringer Ingelheim Investigational Site 118

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Stade : Boehringer Ingelheim Investigational Site 956

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Stade : Boehringer Ingelheim Investigational Site 927

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Stade : Boehringer Ingelheim Investigational Site 928

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Stadthagen : Boehringer Ingelheim Investigational Site 871

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Stadtlohn : Boehringer Ingelheim Investigational Site 757

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Staig : Boehringer Ingelheim Investigational Site 80

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Starkenberg : Boehringer Ingelheim Investigational Site 1102

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Starnberg-Percha : Kardiologische Praxis

Mode Evaluation in Sick Sinus Syndrome Trial (MODEST)

Stauchitz : Boehringer Ingelheim Investigational Site 1293

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Staufenberg : Boehringer Ingelheim Investigational Site 518

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Stegaurach : Boehringer Ingelheim Investigational Site 1334

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Steimel : Boehringer Ingelheim Investigational Site 398

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Steinfeld : Boehringer Ingelheim Investigational Site 921

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Sternberg : Boehringer Ingelheim Investigational Site 1047

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Stockach : Boehringer Ingelheim Investigational Site 41

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Stolberg-Vicht : Boehringer Ingelheim Investigational Site 565

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Stolzenau : Boehringer Ingelheim Investigational Site 885

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Straubing : Boehringer Ingelheim Investigational Site 306

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Strausberg : Boehringer Ingelheim Investigational Site 1173

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Stuhr OT Brinkum : Boehringer Ingelheim Investigational Site 865